1996

Phase I study of ex vivo anti-CD3-stimulated CD4+ T cells, interleukin-2 (IL-2) and cyclophosphamide (CTX) (Meeting abstract).: Proc Annu Meet Am Soc Clin Oncol; 15:A1044 1996. Unique Identifier : AIDSLINE ICDB/196636044; Curti B; Ochoa A; Kopp W; Gause B; Janik J; Fenton R; Miller L; Holmlund J; Creekmore S; Sznol M; Longo D; CRB, NCI, Frederick, MD 21701; A prior CRB trial treated patients (pts) with anti-CD3-stimulated T cells, IL-2 and CTX. In vivo T-cell expansion was achieved, but responses were infrequent. Animal models showed that CD4+ T cells promoted greater antitumor effects than CD8+ or unselected T cells, and
The:mindscape of AIDS : dynamics of transmission.: Cape Town : Percept, 1992 viii, 103 p. : ill Unique Identifier : AIDSLINE CAT/9611934; Perkel AK
AIDS crossing borders : the spread of HIV among migrant Latinos.: Boulder, Colo. : Westview Press, 1996 x, 214 p. : ill Unique Identifier : AIDSLINE CAT/9613074; Mishra SI; Conner RF; Magana JR
AIDS, a family disease : initial guidelines. 1st ed.: Braamfontein : South African National Council for Child and Family Welfare, 1993 62 p Unique Identifier : AIDSLINE CAT/9612427
[Conocimientos sobre aspectos epidemiologicos del S.I.D.A. en los adolescentes gaditanos : grupo de estudio, epidemiologia pediatrica, Cadiz, 1992.]: Salud Cadiz : Escuela Universitaria de Ciencias de la Salud de la Universidad de Cadiz, 1993 104 p. : ill Unique Identifier : AIDSLINE CAT/9602725
[Consequences demographiques du sida en Abidjan : 1986-1992.]: Paris : Centre francais sur la population et le developpement, 1995 xxii, 198 p. : ill (Les etudes du Ceped, ISSN 0993-6157 ; no 10) Unique Identifier : AIDSLINE CAT/9608593; Garenne M
HIV funding watch. Vol. 1, no. 1 (Feb. 6, 1990)-: Austin, Tex. : Reprographics and Library Services Division, 1990- v Unique Identifier : AIDSLINE CAT/9425809
HIV/AIDS cross-reference directory for community educational materials.: [Falls Church, Va. : The Center], 1995 56 p Unique Identifier : AIDSLINE CAT/9612350
[Leben auf Zeit : ein Psychotherapiemanual fur den Umgang mit HIV/Aids und anderen lebensbedrohlichen Krankheiten.] 1. Aufl.: Bern ; Seattle : Verlag Hans Huber, 1996 218 p. : ill (Psychologie Praxis) Unique Identifier : AIDSLINE CAT/9608018; Husler G
[Seksualiteit in Nederland : seksueel gedrag, risico en preventie van AIDS.]: Amsterdam : Swets & Zeitlinger, c1991 263 p. : ill Unique Identifier : AIDSLINE CAT/9403888; Zessen Gv
AIDS and its applied homoeopathy.: Madras, India : Homoeo Vasam Publications, 1995 161 p. : ill Unique Identifier : AIDSLINE CAT/9614663; Muthukumar V
AIDS in the UK : the making of policy, 1981-1994.: New York : Oxford University Press, 1996 xiv, 389 p. : ill Unique Identifier : AIDSLINE CAT/9610150; Berridge V
[Boletim Pela VIDDA.]: Rio de Janeiro : Grupo Pela VIDDA, v Unique Identifier : AIDSLINE CAT/9440267
Meeting to Promote Condom Social Marketing for AIDS/STD Prevention : Yaounde, Cameroon, 2-5 November 1993.: Prevention [Geneva] : Global Programme on AIDS, World Health Organization, [1995] 7 p Unique Identifier : AIDSLINE CAT/9610985
Opportunistic fungal infections in AIDS patients : a clinician's handbook.: [United States?] : SynerMed, c1995 24 p. : ill Unique Identifier : AIDSLINE CAT/9611383
Preventing and mitigating AIDS in Sub-Saharan Africa : research and data priorities for the social and behavioral sciences.: Washington, D.C. : National Academy Press, 1996 xi, 356 p. : ill Unique Identifier : AIDSLINE CAT/9611480; Cohen B; Trussell J; Priorities for Arresting AIDS in Sub-Saharan Africa
Research on educational aspects of AIDS in Uganda : an inventory.: [Kampala] : Unicef ; [Entebbe, Uganda] : Republic of Uganda, The Ministry, [1991] 30 p Unique Identifier : AIDSLINE CAT/9610348; Kristiansen V
Socio-economic and occupational mortality differentials, 1980.: Budapest : Central Statistical Office, 1988- v (Studies in mortality differentials ; 4) Unique Identifier : AIDSLINE CAT/9611887; Varga A
Transfusion-associated AIDS.: Tucson, AZ : Lawyers & Judges Pub. Co., c1995 xv, 346 p. : forms Unique Identifier : AIDSLINE CAT/9608191; Jenner RK; Burgess SJ
[Visszaemlekezeseim.]: Debrecen : DOTE Rekori Hivatala, 1983 193 p. : ill., ports Unique Identifier : AIDSLINE CAT/9400849; Ladanyi J
The:sociology of HIV transmission.: London ; Thousand Oaks, Calif. : Sage Publications, 1995 ix, 158 p Unique Identifier : AIDSLINE CAT/9612727; Bloor M
AIDS and society.: Upper Saddle River, N.J. : Prentice Hall, c1996 xiv, 370 p. : ill., ports Unique Identifier : AIDSLINE CAT/9614323; Smith JM
AIDS : the politics and policy of disease.: Upper Saddle River, N.J. : Prentice Hall, c1996 viii, 152 p. : ill Unique Identifier : AIDSLINE CAT/9614316; Theodoulou SZ
Evaluation of local HIV service delivery : issues, approaches & strategies under Title I, the Ryan White Care Act : a meeting sponsored by Division of HIV Services and Office of Science & Epidemiology, Bureau of Health Resources Development, Health Resources and Services Administration.: [Rockville, Md.? : Health Resources & Services Administration, 1996] i, 52 p. : ill Unique Identifier : AIDSLINE CAT/9615499; Eilbert K
Grief and AIDS.: Chichester ; New York : Wiley, c1995 xi, 215 p Unique Identifier : AIDSLINE CAT/9612723; Sherr L
[Prevention du sida en milieu specialise.]: Ramonville Saint-Agne : Eres, c1996 175 p. : ill Unique Identifier : AIDSLINE CAT/9615445; Greacen T
Resource manual for support of dentists with HBV, HIV, TB and other infectious diseases.: Chicago, Ill. : The Council, 1995 iii, 63 p Unique Identifier : AIDSLINE CAT/9604741
Criteria for the medical care of children and adolescents with HIV infection.: [New York] : AIDS Institute, New York State Dept. of Health, [1995] xvii, 259 p Unique Identifier : AIDSLINE CAT/9615278
Designing new antiviral drugs for AIDS : HIV-1 protease and its inhibitors.: Austin : R.G. Landes, 1996 (Bioscience reports) Unique Identifier : AIDSLINE CAT/9615936; March D; Fairlie DP
Home care guide for HIV/AIDS : how to care for family and friends at home.: Philadelphia : American College of Physicians, c1995 Unique Identifier : AIDSLINE CAT/9616219; Houts PS
Program advisory : use of zidovudine (ZDV) to reduce perinatal HIV transmission in HRSA-funded programs.: [Washington, D.C.?] : U.S. Dept. of Health & Human Services, Public Health Service, Health Resources & Services Administration, [1995] ii, 30 p. : ill Unique Identifier : AIDSLINE CAT/9609368
HIV and AIDS newsletter. Vol. 1, #1-v. 3, #1.: [Calgary, Alta.] : The Society, [1990?-1992?] 3 v Unique Identifier : AIDSLINE CAT/9425865
HIV briefs.: Project [Darlinghurst, NSW?] : The Project, v Unique Identifier : AIDSLINE CAT/9425623
HIV herald : monthly magazine of the AFAO National Treatments Project.: Project Darlinghurst, NSW : The Project, v Unique Identifier : AIDSLINE CAT/9425575
HI:V frontline : a message to the mental health and health-care professionals who counsel people living with HIV. #1 (Apr. 1991)-: Prevention Studies San Francisco, Calif. : L. McKusick, 1991- v Unique Identifier : AIDSLINE CAT/9425632
AIDS and the ADA: physician liability for discriminatory nontreatment or referral of AIDS patients.: J Cardiovasc Manag. 1996 Jul-Aug;7(4):12, 14-5. Unique Identifier : AIDSLINE AHA/96364651; Hirsch WR
What to do about hives.: Contemp Pediatr. 1996 Aug;13(8):93-4. Unique Identifier : AIDSLINE HTA/96343729; Schmitt BD; General Consultative Services, Children's Hospital of Denver,; University of Colorado School of Medicine, USA.
Social context of HIV infection in Uganda.: Health Transit Rev. 1995;5 Suppl:1-26. Unique Identifier : AIDSLINE HTA/96364369; Adeokun LA; Twa-Twa J; Ssekiboobo A; Nalwadda R; Institute of Statistics and Applied Economics, Makerere; University, Kampala, Uganda.; Some of the important policy and research implications of accumulating HIV/AIDS data are being ignored because of the attraction of social science research focused on the multiple sexual mechanism of infection and transmission. Attention is drawn to the other policy and research issues relating to information on the
The effects of HIV and AIDS on fertility in East and Central Africa.: Health Transit Rev. 1995;5 Suppl:179-89. Unique Identifier : AIDSLINE HTA/96364372; Setel P; National Centre for Epidemiology and Population Health,; Australian National University.; Concern has been expressed about the fertility of people infected with HIV: the worry has been that on learning of their condition, HIV-affected individuals may attempt to accomplish unmet reproductive goals knowing that they will not live a normal life span. This article addresses the potential effects of AIDS on fer
Impact of AIDS on the family and mortality in Uganda.: Health Transit Rev. 1995;5 Suppl:191-200. Unique Identifier : AIDSLINE HTA/96364373; Mukiza-Gapere J; Ntozi JP; Department of Population Studies, Institute of Statistics and; Applied Economics, Makerere University.
Impact of AIDS on marriage patterns, customs and practices in Uganda.: Health Transit Rev. 1995;5 Suppl:201-8. Unique Identifier : AIDSLINE HTA/96364374; Mukiza-Gapere J; Ntozi JP; Department of Population Studies, Institute of Statistics and; Applied Economics, Makerere University.
Care for AIDS orphans in Uganda: findings from focus group discussions.: Health Transit Rev. 1995;5 Suppl:245-52. Unique Identifier : AIDSLINE HTA/96364375; Ntozi JP; Mukiza-Gapere J; Department of Population Studies, Institute of Statistics and; Applied Economics, Makerere University.
The declining HIV seroprevalence in Uganda: what evidence?: Health Transit Rev. 1995;5 Suppl:27-33. Unique Identifier : AIDSLINE HTA/96364370; Konde-Lule JK; Institute of Public Health, Makerere University, Kampala.
On second thought: a Canadian reflection. Informing after the fact: AIDS, confidentiality, and the duty to warn.: HEC Forum. 1996 Jul;8(4):212-20. Unique Identifier : AIDSLINE AHA/96360845; Flagel DC
AIDS--meeting the challenge of home care.: Caring. 1996 Aug;15(8):10-2. Unique Identifier : AIDSLINE AHA/96365104; Taylor E; Visiting Nurse Association of Washington, DC, USA.
Crossing cultural barriers to care for people with AIDS.: Caring. 1996 Aug;15(8):14-8. Unique Identifier : AIDSLINE AHA/96365105; Cuthbert-Allman C; Chausse M; Visiting Nurse Association of Boston, USA.; The delivery of high-quality home care to HIV/AIDS patients is often complicated by the cultural barriers present when caring for minority populations. Developing trust, listening skills, and a nonjudgmental approach are essential to providers who care for people of varied cultural backgrounds.
Creating partners in HIV care.: Caring. 1996 Aug;15(8):20-4. Unique Identifier : AIDSLINE AHA/96365106; Adams J; Founder of Home Care Companions, Inc, San Francisco, CA, USA.; Home care teams caring for people with AIDS often must depend on informal caregivers to help their patients. If the informal caregivers have better tools to help, patients are more likely to get the best care possible. This training program for care partners is a perfect way to provide those tools.
Pain management and psychosocial issues in HIV and AIDS.: Caring. 1996 Aug;15(8):26-35. Unique Identifier : AIDSLINE AHA/96365107; Breitbart W; Memorial Sloan-Kettering Cancer Center, New York, NY, USA.
Nutrition for in-home AIDS patients.: Caring. 1996 Aug;15(8):36-8. Unique Identifier : AIDSLINE AHA/96365108; Sachs KM; Visiting Nurse Association of Washington, DC, USA.; Early medical nutrition intervention with in-home AIDS patients can help prolong and improve the quality and quantity of their lives. Teaching the basics of good nutrition both early on as well as in the later stages of AIDS can save thousands of health care dollars through preventive care at home.
Pediatric AIDS program addresses whole families.: Caring. 1996 Aug;15(8):42-4. Unique Identifier : AIDSLINE AHA/96365109; Dobson AS; Clarke N; Visiting Nurse Association of South Central Connecticut, Inc.,; New Haven, USA.; Families of children with AIDS are often at risk for substance abuse, child neglect, and homelessness. Effective service delivery to the pediatric AIDS population requires a holistic, team-oriented approach for the whole family.
Needle exchange programs benefit the community.: Caring. 1996 Aug;15(8):46-7. Unique Identifier : AIDSLINE AHA/96365110; Whitteker WB; San Diego Clean Needle Exchange, CA, USA.; Needle exchange programs, illegal in many communities, provide HIV-prevention services to a hard-to-reach population--injection drug users (IDU). Reaching IDUs, who are among society s most at-risk members for HIV infection, protects the health of the community at large.
Passive hyperimmune therapy: buying time at what cost?: Caring. 1996 Aug;15(8):48-50. Unique Identifier : AIDSLINE AHA/96365111; Chavez C; Some AIDS physicians are now turning to passive hyperimmune therapy as an alternative to try to protect and rebuild AIDS patients ravaged immune systems. This is a labor-intensive and expensive treatment that raises many questions.
Home HIV tests: the need for regulation.: Caring. 1996 Aug;15(8):52-5. Unique Identifier : AIDSLINE AHA/96365112; Tamborlane TA; Kunz DA; Theodosia A. Tamborlane, P.C., Mountainside, NJ, USA.; In-home testing for HIV/AIDS will be available nationwide in early 1997. Because laws regulating these over-the-counter test kits vary widely from state to state, national uniform regulations are needed to safeguard the rights of consumers and to protect health care providers from professional liability.
HIV/AIDS resources on the Internet.: Caring. 1996 Aug;15(8):56-63. Unique Identifier : AIDSLINE AHA/96365113; Davis NA; National Association for Home Care, Washington, DC, USA.; Both HIV/AIDS patients and their caregivers can find a wealth of information about HIV and AIDS on the Internet, if they know where to look for it. Below is a guide to get both professionals and lay people started on their search for HIV/AIDS information.
Congress reauthorizes the Ryan White CARE (Comprehensive AIDS Resources Emergency) Act.: Caring. 1996 Aug;15(8):68-9. Unique Identifier : AIDSLINE AHA/96365114; Sokol EW
Finance a humane system of AIDS care.: Caring. 1996 Aug;15(8):7. Unique Identifier : AIDSLINE AHA/96365103
Cost effectiveness of antituberculosis interventions.: Pharmacoeconomics. 1995 Nov;8(5):385-99. Unique Identifier : AIDSLINE HTA/96275164; Castelo A; Mathiasi PA; Iunes R; Kritski AL; Dalcolmo M; Fiuza de Melo F; Drummond M; Universidade Federal de Sao Paulo, Brazil.; The treatment of tuberculosis (TB) is ranked as the most cost effective of all therapeutic programmes in terms of cost per year of life saved. Nevertheless, TB kills or debilitates more adults aged between 15 and 59 years than any other disease in the world; furthermore, about 2 to 4% of the burden of disease, 7% of a
The economic costs of caring for people with HIV infection and AIDS in England and Wales.: Pharmacoeconomics. 1996 Apr;9(4):332-40. Unique Identifier : AIDSLINE HTA/96321915; Petrou S; Dooley M; Whitaker L; Beck E; Kupek E; Wadsworth J; Miller D; Renton A; Academic Department of Public Health, St Mary's Hospital Medical; School, London, England.; The objectives of this study were firstly to estimate total lifetime care costs for an individual with HIV/AIDS, and secondly to estimate the total costs of caring people with HIV infection and AIDS in England and Wales between 1992 and 1997 inclusive. Questionnaires and monthly diaries were used to collate data on he
Economic analysis at the global level: a resource requirement model for HIV prevention in developing countries.: Health Policy. 1996 Oct;38(1):45-65. Unique Identifier : AIDSLINE AHA/96383676; Broomberg J; Soderlund N; Mills A; Monitor Company, Johannesburg, South Africa.; Agencies operating at the international level have a need for economic analysis to help develop global health policies and determine resource requirements to support their advocacy efforts. This paper presents work commissioned by the Global Programme on AIDS to estimate the total resource requirements of implementing
HIV-preventive cognitions amongst secondary school students in Uganda.: Health Educ Res. 1995 Jun;10(2):155-62. Unique Identifier : AIDSLINE HTA/96368393; Abraham SC; Rubaale TK; Kipp W; Department of Epidemiology and Public Health, Ninewells Hospital; and Medical School, Dundee, UK.; A self-completion questionnaire was used to survey HIV-preventive cognitions among secondary school students in Kabarole district, Uganda . An encouraging pattern of HIV-preventive beliefs was observed, suggesting that health education efforts have been effective in establishing bas
Staff stress in AIDS prevention and service organizations: implications for health education practice.: Health Educ Res. 1995 Jun;10(2):163-77. Unique Identifier : AIDSLINE HTA/96368394; Janz NK; Wren PA; Israel BA; Health Behavior and Health Education Department, School of Public; Health, University of Michigan, Ann Arbor 48109-2029, USA.; The purpose of this study was to identify the frequency of staff stressors and their association with programmatic factors in 51 AIDS prevention and service projects funded by the Robert Wood Johnson Foundation. The methodology included both quantitative (i.e. closed-ended survey questions) and qualitative (i.e. in-de
Criteria for the appropriate drug utilisation of immunoglobulin.: Pharmacoeconomics. 1996 May;9(5):417-29. Unique Identifier : AIDSLINE HTA/96358349; Thurmann P; Harder S; Department of Clinical Pharmacology, University Hospital; Frankfurt/Main, Germany.; Intravenous immunoglobulins (IVIGs) are prepared from human plasma pools and further modified enzymatically or chemically. Despite careful selection of donors and inclusion of effective virus elimination steps in the production process, contamination with hepatitis C virus can still occur. IVIGs possess most of the ch
Blood & politics.: CAP Today. 1996 Mar;10(3):20, 22-4. Unique Identifier : AIDSLINE HTA/96387407; Titus K
Knowing when and how to notify donors, recipients.: CAP Today. 1996 Apr;10(4):63-7, 70. Unique Identifier : AIDSLINE HTA/96387412; Chapman B
Current good manufacturing practices for blood and blood components: notification of consignees receiving blood and blood components at increased risk for transmitting HIV infection--FDA. Final rule.: Fed Regist. 1996 Sep 9;61(175):47413-23. Unique Identifier : AIDSLINE AHA/96406120; The Food and Drug Administration ( FDA ) is amending the biologics regulations to require that blood establishments (including plasma establishments) prepare and follow written procedures for appropriate action when it is determined that Whole Blood, blood components (including recovere
Medicare and Medicaid programs: hospital standard for potentially HIV infectious blood and blood products--HCFA. Final rule.: Fed Regist. 1996 Sep 9;61(175):47423-34. Unique Identifier : AIDSLINE AHA/96406121; This final rule requires hospitals participating in the Medicare and Medicaid programs to take appropriate action when the hospitals learn that they have received whole blood, blood components (including recovered plasma), source plasma, and source leukocytes (hereafter referred to as blood or blood products) that are
Innovative new equipment lowers risks of needlesticks.: Health Facil Manage. 1996 Oct;9(10):68, 70, 72 passim. Unique Identifier : AIDSLINE AHA/96406128; Garvin M; University of Iowa Hospitals and Clinics, Iowa City, USA.
AIDS and neuro-ophthalmology.: Curr Opin Ophthalmol. 1995 Dec;6(6):34-40. Unique Identifier : AIDSLINE HTA/96358753; Currie J; Drug and Alcohol Services, Westmead Hospital, Australia.
Ocular manifestations of AIDS.: Curr Opin Ophthalmol. 1995 Dec;6(6):82-7. Unique Identifier : AIDSLINE HTA/96358760; Park KL; Smith RE; Rao NA; Doheny Eye Institute, Los Angeles, California, USA.; AIDS causes severe depression of the immune system through selective infection of CD4+ T lymphocytes. As such, certain infections and neoplasms occur in these patients often with ocular involvement. Among these, cytomegalovirus retinitis is by far the most common and remains a lead
The consequence of land mines on public health.: Prehospital Disaster Med. 1996 Jan-Mar;11(1):2-10. Unique Identifier : AIDSLINE HTA/96342631; Kakar F; Bassani F; Romer CJ; Gunn SW; Division of Emergency and Humanitarian Action, World Health; Organization (WHO), Geneva, Switzerland.; An estimated 110 million land mines scattered in 64 countries continue to terrorize people and destroy human lives long after wars and fighting have ceased. Despite efforts to clear these devices, their numbers continue to increase and their presence constitutes a substantial threat to public health in affected countr
Pharmacoeconomics of Pneumocystis carinii pneumonia in HIV-infected and HIV-noninfected patients.: Pharmacoeconomics. 1996 Jul;10(1):72-8. Unique Identifier : AIDSLINE HTA/96368413; Nicolau DP; Ross JW; Quintiliani R; Nightingale CH; Department of Pharmacy, Hartford Hospital, Connecticut, USA.; Despite the proven effectiveness of Pneumocystis carinii pneumonia (PCP) prophylaxis in both HIV-infected and HIV-noninfected patients, PCP remains an important cause of serious pulmonary infection. Because PCP is a frequent event requiring inpatient admission at our institution, we conducted a study to define the pha
Estimating the cost effectiveness of atovaquone versus intravenous pentamidine in the treatment of mild-to-moderate Pneumocystis carinii pneumonia.: Pharmacoeconomics. 1996 Jun;9(6):525-34. Unique Identifier : AIDSLINE HTA/96339251; Zarkin GA; Bala MV; Wood LL; Bennett CL; Simpson K; Dohn MN; Center for Economics Research, Research Triangle Institute,; Research Triangle Park, North Carolina, USA.; Pneumocystis carinii pneumonia (PCP) is the most common severe opportunistic infection, and one of the most costly, among people with AIDS. Over 50% of patients experience toxic effects of the major anti-PCP medications- cotrimoxazole (trimethoprim-sulfamethoxazole) and pentamidine. Recently, the US Food and Drug Admi
AIDS policies and procedures. Pike, Plymouth Meeting, PA 19462, USA.: In: Healthcare Risk Control. Volume 1. Plymouth Meeting, PA : ECRI, 1996. 20 p. (SAQ; no. 8) Unique Identifier : AIDSLINE HTX/96924101; A hospital s legal responsibilities with regard to human immunodeficiency virus (HIV) and acquired immunodeficiency syndrome (AIDS) are constantly being redefined. A crucial risk management strategy is the careful crafting and updating of policies that comply with relevant laws, guidelines, and regulations and that t
Preventing accidental needlesticks and sharps injuries. Pike, Plymouth Meeting, PA 19462, USA.: In: Healthcare Risk Control. Volume 1. Plymouth Meeting, PA : ECRI, 1996. 10 p. (SAQ; no. 9) Unique Identifier : AIDSLINE HTX/96924102; Accidental needlesticks and other sharp-object injuries occur frequently in healthcare facilities, placing at risk those providers who use the sharps (e.g., physicians, nurses) and those who may come in contact with the sharps after use (e.g., housekeeping personnel). A number of clinical procedures and housekeeping
Issues and implications in the counseling of survivors of multiple AIDS-related loss.: Death Stud. 1996 Jul-Aug;20(4):389-413. Unique Identifier : AIDSLINE HTA/96926373; Nord D; Maple Valley, Washington, USA.; Survivors of multiple AIDS-related loss face a unique phenomenon for which existing theories and diagnostic criteria regarding grief and trauma are inadequate. Unresolved grief and complicated bereavement are normal responses to multiple loss. This distinctive experience and the resulting symptoms have implications f
Breaking barriers, building bridges. [videorecording]: Communities Washington, D.C. : Dept. of Health and Human Services, [1994] 16 videocassettes (20 hr., 20 min., 51 sec) : sd., col. ; 1/2 in Unique Identifier : AIDSLINE AV/9611093
The:second decade of AIDS : [a mental health practice training video]. [videorecording]: [Williston, VT] : Hatherleigh Co., c1996 2 videocassettes (4 hr.) : sd., col. ; 1/2 in Unique Identifier : AIDSLINE AV/9612472; Shernoff M
Age of AIDS. [videorecording]: [Washington, D.C. : Gallaudet University], c1991 1 videocassette (28 min.) : sd., col. ; 1/2 in Unique Identifier : AIDSLINE AV/9610173; (Producer) Experts on deaf health issues and deaf people with AIDS discuss community services and prevention for the deaf community.
Living with HIV : an overview. [videorecording]: Princeton, NJ : Films for the Humanities & Sciences, c1996 1 videocassette (21 min.) : sd., col. ; 1/2 in (Cutting edge medical report) Unique Identifier : AIDSLINE AV/9615199; (Producer) The most recent advancements in the research and treatment of AIDS/HIV and opportunistic infections are the subject of this program. Featuring four respected medical professionals in AIDS research, the program clarifies the common misconceptions about HIV/AIDS of the general public as well as the medical
HIV/AIDS surveillance data base. Windows version, version 1.0. [computer file]: [Washington, D.C.] : U.S. Bureau of the Census, 1996 7 computer disks ; 3 1/2 in. + 1 guide (36 p.) Unique Identifier : AIDSLINE AV/9612084; (Producer) Represents the latest major update to the HIV/AIDS surveillance data base. It incorporates all available epidemiological information for developing countries presented at the Third International Conference on AIDS in Asia and the Pacific, Chiang Mai, Thailand , Septem
Indinavir: lightening the load. Clearinghouse, AIDS Newsletter Database, P.O. Box 6003, Rockville, MD 20849-6003. 800-458-5231 ext. 5714.: J Int Assoc Physicians AIDS Care. 1996 Aug;2(8):6-11. Unique Identifier : AIDSLINE AIDS/96701849; MacDougall DS; Some of the most dramatic reductions in HIV viremia have been observed among patients treated with indinavir sulfate ( Crixivan ). How the hypothesis that HIV protease maintains the inf
1996 National Farmworker Health Conference. Clearinghouse, AIDS Newsletter Database, P.O. Box 6003, Rockville, MD 20849-6003. 800-458-5231 ext. 5714.: J Int Assoc Physicians AIDS Care. 1996 Aug;2(8):12-4, 16, 19. Unique Identifier : AIDSLINE AIDS/96701850; Dougherty S; Health care providers who serve farmworkers are challenged by the geographical distribution of their clients, language differences, and opposition from Congress. At the 1996 National Farmworker Health Conference, clinicians and researchers considered how to deal with these challenges. The number of U.S. migrant and se
Tuberculosis in farmworkers. Clearinghouse, AIDS Newsletter Database, P.O. Box 6003, Rockville, MD 20849-6003. 800-458-5231 ext. 5714.: J Int Assoc Physicians AIDS Care. 1996 Aug;2(8):15. Unique Identifier : AIDSLINE AIDS/96701851; Nist A; Collier County Public Health Unit, Naples, FL.; It is believed that the HIV epidemic will increasingly fuel the TB epidemic in farmworkers in the years to come as it increases the likelihood that dormant TB infection will progress to active TB disease. Several case studies of TB in HIV-positive farmworkers show the problems inherent in maintaining treatment, reveal
The ascendancy--and the future--of combination antiretroviral and immunomodulatory therapies. Clearinghouse, AIDS Newsletter Database, P.O. Box 6003, Rockville, MD 20849-6003. 800-458-5231 ext. 5714.: J Int Assoc Physicians AIDS Care. 1996 Aug;2(8):20-5. Unique Identifier : AIDSLINE AIDS/96701852; Cooper DA; University of New South Wales, Sydney, Australia.; There has been a recent demise in antiretroviral monotherapy and the ascendancy of combination therapy for HIV-infected patients. A few of the trials that established the change and a few that may contribute to the continuing evolution of antiretroviral therapy are bri
FDA approves cidofovir for treatment of CMV retinitis. Food and Drug Administration. Clearinghouse, AIDS Newsletter Database, P.O. Box 6003, Rockville, MD 20849-6003. 800-458-5231 ext. 5714.: J Int Assoc Physicians AIDS Care. 1996 Aug;2(8):30. Unique Identifier : AIDSLINE AIDS/96701853; In June 1996 the Food and Drug Administration ( FDA ) granted marketing clearance of cidofovir injection (Vistide) for the treatment of CMV retinitis in patients with AIDS. Two studies demonstrated cidofovir s ability to slow prog
Two worlds, two hopes. Clearinghouse, AIDS Newsletter Database, P.O. Box 6003, Rockville, MD 20849-6003. 800-458-5231 ext. 5714.: AIDS Clin Care. 1996 Sep;8(9):71-2. Unique Identifier : AIDSLINE AIDS/96701854; Zuger A; The International Conference on AIDS, held in Vancouver in July 1996, showed two distinct themes. One was optimism, and researchers were cheered by the advent of viral load testing, the development of other antiretroviral drugs, and new schemes to slow the progression of the disease. However, at the same time that the
A new focus on primary HIV infection. Clearinghouse, AIDS Newsletter Database, P.O. Box 6003, Rockville, MD 20849-6003. 800-458-5231 ext. 5714.: AIDS Clin Care. 1996 Sep;8(9):72, 75. Unique Identifier : AIDSLINE AIDS/96701855; Hecht F; There are two potential goals of very early treatment of HIV infection. One is to see whether aggressive treatment during the primary phases of infection can improve the long-term course. The other is to test the feasibility of eradicating HIV infection. Eradication may be simpler in newly-infected patients who are li
A virologist's view from Vancouver. Clearinghouse, AIDS Newsletter Database, P.O. Box 6003, Rockville, MD 20849-6003. 800-458-5231 ext. 5714.: AIDS Clin Care. 1996 Sep;8(9):73, 75. Unique Identifier : AIDSLINE AIDS/96701856; Japour A; Researchers and clinicians at the Vancouver International Conference on AIDS noted that remarkable advances have been made in antiretroviral therapy, and all classes of drugs show viral load reductions. Patients need to be increasingly aware of the need for complete compliance with their drug regimens, as resistance i
Continued therapeutic improvements for OIs. Clearinghouse, AIDS Newsletter Database, P.O. Box 6003, Rockville, MD 20849-6003. 800-458-5231 ext. 5714.: AIDS Clin Care. 1996 Sep;8(9):74. Unique Identifier : AIDSLINE AIDS/96701857; Currier J; Several presentations at the Vancouver International Conference on AIDS reported continued improvements in the treatment of opportunistic infections. New and ongoing studies for MAC were reported, including one that alerted clinicians to the dangers of using high-dose clarithromycin for therapy. PCP, for which there a
Nelfinavir protease inhibitor study recruiting. Clearinghouse, AIDS Newsletter Database, P.O. Box 6003, Rockville, MD 20849-6003. 800-458-5231 ext. 5714.: AIDS Treat News. 1996 Aug 23;(No 253):1. Unique Identifier : AIDSLINE AIDS/96701858; Agouron Pharmaceuticals, Inc. is recruiting 200 participants in 8 U.S. cities for its clinical trial for nelfinavir (VIRACEPT), an experimental protease inhibitor. Volunteers must already be taking a nucleoside analog drug such as
Five-drug or six-drug antiretroviral therapy--conversation with Steven Scheibel, M.D. [interview by John S. James] Clearinghouse, AIDS Newsletter Database, P.O. Box 6003, Rockville, MD 20849-6003. 800-458-5231 ext. 5714.: AIDS Treat News. 1996 Aug 23;(No 253):1-2. Unique Identifier : AIDSLINE AIDS/96701859; Scheibel S; In an interview with AIDS Treatment News, Steven F. Scheibel, M.D. discusses the results of two small studies in San Francisco that reported good HIV suppression with regimens of five-drug and six-drug antiretroviral therapy. The studies included a clinical trial of 6 patients infected with HIV-1 within the past 6 mon
1592 -- new experimental antiretroviral. Clearinghouse, AIDS Newsletter Database, P.O. Box 6003, Rockville, MD 20849-6003. 800-458-5231 ext. 5714.: AIDS Treat News. 1996 Aug 23;(No 253):2-3. Unique Identifier : AIDSLINE AIDS/96701860; James JS; Glaxo Wellcome is developing a nucleoside analog which may have a stronger anti-HIV effect than other approved nucleoside analogs. In phase I/II human trials, 1592U89 (also called 1592) has already been administered to 80 volunteers with CD4 counts of 200-500 who had less
Medical marijuana: California update. Clearinghouse, AIDS Newsletter Database, P.O. Box 6003, Rockville, MD 20849-6003. 800-458-5231 ext. 5714.: AIDS Treat News. 1996 Aug 23;(No 253):3-5. Unique Identifier : AIDSLINE AIDS/96701861; James JS; The Cannabis Buyers Club in San Francisco remains closed after it was raided by the office of California Attorney General Dan Lungren. Many individuals with serious illnesses such as AIDS and cancer are without safe access to medical marijuana to relieve the symptoms of their diseases. The need for access to medicina
Arizona court upholds HIV testing of juvenile convicted of sex offense. Clearinghouse, AIDS Newsletter Database, P.O. Box 6003, Rockville, MD 20849-6003. 800-458-5231 ext. 5714.: AIDS Policy Law. 1996 Sep 6;11(16):1, 10. Unique Identifier : AIDSLINE AIDS/96701862; An Arizona State Appeals Court ruled that a State law forcing juvenile sex offenders to submit to HIV-antibody testing does not violate Fourth Amendment protection. The State s interest in helping victims to learn the HIV status of their attacker outweighs the attacker s privacy interests. However, only the victim or
Union seniority supersedes ADA on issue of job accommodation. Clearinghouse, AIDS Newsletter Database, P.O. Box 6003, Rockville, MD 20849-6003. 800-458-5231 ext. 5714.: AIDS Policy Law. 1996 Sep 6;11(16):1, 11. Unique Identifier : AIDSLINE AIDS/96701863; The 7th U.S. Circuit Court of Appeals ruled that the Americans with Disabilities Act (ADA) does not require an employer to violate a union s seniority system in an attempt to provide a reasonable accommodation to a worker with a disability. Terry Eckles, diagnosed with epilepsy, could only return to work based on cert
Lawyer fined for not disclosing client's HIV infection. Clearinghouse, AIDS Newsletter Database, P.O. Box 6003, Rockville, MD 20849-6003. 800-458-5231 ext. 5714.: AIDS Policy Law. 1996 Sep 6;11(16):2. Unique Identifier : AIDSLINE AIDS/96701864; Robert Griffith, handling the wrongful death lawsuit of a Massachusetts inmate, has been fined $15,000 because he did not disclose to the defense that the inmate was HIV-positive. Inmate Morris Pina, Jr. died after being beaten by police officers; he was refused medical care for the injuries. U.S. District Judge Mark
HIV not communicable in restaurant setting, court rules. Clearinghouse, AIDS Newsletter Database, P.O. Box 6003, Rockville, MD 20849-6003. 800-458-5231 ext. 5714.: AIDS Policy Law. 1996 Sep 6;11(16):3. Unique Identifier : AIDSLINE AIDS/96701865; The case of Sanchez v. Lagoudakis may be brought before the Michigan Supreme Court for the third time. In 1988, restaurateur Kostas Lagoudakis ordered then waitress Dorene Sanchez to undergo an HIV-antibody test at her own expense because several customers suspected that she might be HIV-positive. Sanchez tested negat
Fear of AIDS is actionable if reckless conduct is alleged. Clearinghouse, AIDS Newsletter Database, P.O. Box 6003, Rockville, MD 20849-6003. 800-458-5231 ext. 5714.: AIDS Policy Law. 1996 Sep 6;11(16):4-5. Unique Identifier : AIDSLINE AIDS/96701866; A New Jersey appeals court allowed a plaintiff to seek damages for fear of contracting HIV even though there was no evidence of actual exposure to the virus. Office cleaner Karen Williamson sued the medical offices of Drs. Waldman, Feldman, and Losman after puncturing her hand on a lancet that had been improperly disp
Statement in open court forecloses couple's privacy claim. Clearinghouse, AIDS Newsletter Database, P.O. Box 6003, Rockville, MD 20849-6003. 800-458-5231 ext. 5714.: AIDS Policy Law. 1996 Sep 6;11(16):6-7. Unique Identifier : AIDSLINE AIDS/96701867; A three-judge panel of the 6th U.S. Circuit Court of Appeals ruled that once a person discloses his or her HIV status in the public domain, the information is no longer private. This ruling settles a lawsuit filed by John and Jane Doe. Mr. Doe, sentenced to 6 months in jail, persuaded the sentencing judge to grant him
Court poses question: is policy void if obtained by fraud? Clearinghouse, AIDS Newsletter Database, P.O. Box 6003, Rockville, MD 20849-6003. 800-458-5231 ext. 5714.: AIDS Policy Law. 1996 Sep 6;11(16):7. Unique Identifier : AIDSLINE AIDS/96701868; The 1st U.S. Circuit Court of Appeals asked Massachusetts highest court to determine whether an insurance company can void an incontestable life insurance policy if it was obtained by fraud. No case law exists to cover the issues in this dispute. The option by the State s Supreme Judicial Court could impact Massachus
Court says HIV is an illness, not a pre-existing condition. Clearinghouse, AIDS Newsletter Database, P.O. Box 6003, Rockville, MD 20849-6003. 800-458-5231 ext. 5714.: AIDS Policy Law. 1996 Sep 6;11(16):8. Unique Identifier : AIDSLINE AIDS/96701869; A three-judge panel of the Tennessee Court of Appeals upheld a lower court s dismissal of a lawsuit filed by Krzystof Krakowiak. Krakowiak s insurer, Paul Revere Life Insurance Company, refused to pay disability benefits after learning that he had failed to state in his application that he was HIV-positive. The policy
Evidence of a disability renders policy contestable, judge says. Clearinghouse, AIDS Newsletter Database, P.O. Box 6003, Rockville, MD 20849-6003. 800-458-5231 ext. 5714.: AIDS Policy Law. 1996 Sep 6;11(16):8. Unique Identifier : AIDSLINE AIDS/96701870; U.S. District Judge Justin Quackenbush of California upheld the validity and incontestability clause of an insurance policy that allowed an insurer to back out if the policy holder developed any disability that prevented him from working during the first two years of coverage. Mutual Life Insurance Company of New York
Rhode Island kills bill forcing inmates to reveal HIV status. Clearinghouse, AIDS Newsletter Database, P.O. Box 6003, Rockville, MD 20849-6003. 800-458-5231 ext. 5714.: AIDS Policy Law. 1996 Sep 6;11(16):9. Unique Identifier : AIDSLINE AIDS/96701871; Rhode Island Governor Lincoln Almond vetoed legislation allowing State prison guards to learn the names of adult inmates infected with HIV. The bill was brought before the governor for two consecutive years. Almond stated that the disclosure requirement, supported by the Brotherhood of Correctional Officers, is not me
Court overturns ruling on housing of homeless with HIV. Clearinghouse, AIDS Newsletter Database, P.O. Box 6003, Rockville, MD 20849-6003. 800-458-5231 ext. 5714.: AIDS Policy Law. 1996 Sep 6;11(16):9. Unique Identifier : AIDSLINE AIDS/96701872; The New York Court of Appeals struck down a lower court finding that New York City s shelter program for the homeless with HIV failed to promise minimum protection against tuberculosis (TB). A class action led by Kenneth Mixon claimed that people who do not fit the Federal definition of AIDS are placed in a segregated
Bus driver sues. Clearinghouse, AIDS Newsletter Database, P.O. Box 6003, Rockville, MD 20849-6003. 800-458-5231 ext. 5714.: AIDS Policy Law. 1996 Sep 6;11(16):12. Unique Identifier : AIDSLINE AIDS/96701873; A bus driver, known as John Doe, sued his employer, alleging that he was fired when he voluntarily disclosed that he was HIV-positive and needed a rest from the long hours of driving. The driver sued for back wages, benefits, and compensatory and punitive damages under the New Jersey Law Against Discrimination. Academ
KS treatment inches forward. Clearinghouse, AIDS Newsletter Database, P.O. Box 6003, Rockville, MD 20849-6003. 800-458-5231 ext. 5714.: Posit Aware. 1996 Sep/Oct;7(5):9. Unique Identifier : AIDSLINE AIDS/96701874; Vazquez E; A study of doxorubicin hydrochloride (Doxil) showed effectiveness in treating Kaposi s sarcoma (KS) with less toxicity than seen in patients using the combination bleomycin and vincristine (BV). The manufacturer, Sequus Pharmaceuticals, plans to file for Food and Drug Administratio
Nevirapine approval expands combo possibilities--and HIV suppression. Clearinghouse, AIDS Newsletter Database, P.O. Box 6003, Rockville, MD 20849-6003. 800-458-5231 ext. 5714.: Posit Aware. 1996 Sep/Oct;7(5):9. Unique Identifier : AIDSLINE AIDS/96701875; Vazquez E; The Food and Drug Administration ( FDA ) granted accelerated approval to nevirapine ( Viramune ) on June 24, 1996. Nevirapine is the first of another new
Take a load off. Clearinghouse, AIDS Newsletter Database, P.O. Box 6003, Rockville, MD 20849-6003. 800-458-5231 ext. 5714.: Posit Aware. 1996 Sep/Oct;7(5):10-1. Unique Identifier : AIDSLINE AIDS/96701876; McGuire S; Viral load testing is a valuable tool for clinicians and physicians to use to determine how well a treatment regimen is working. A large body of evidence now shows that doctors can use viral load to make decisions about HIV treatments. Approved tests are described, and recommended guidelines for the use of the data ar
Another protease inhibitor proves highly effective. Clearinghouse, AIDS Newsletter Database, P.O. Box 6003, Rockville, MD 20849-6003. 800-458-5231 ext. 5714.: Posit Aware. 1996 Sep/Oct;7(5):11. Unique Identifier : AIDSLINE AIDS/96701877; Prescott LM; Nelfinavir ( Viracept ) is a well-tolerated and effective protease inhibitor, especially when used in combination with nucleoside analogues. When used in triple combination, it is even more effective. An ongoing trial showed that 11 patients showed no d
Opportunistic infections. Clearinghouse, AIDS Newsletter Database, P.O. Box 6003, Rockville, MD 20849-6003. 800-458-5231 ext. 5714.: Posit Aware. 1996 Sep/Oct;7(5):12-3. Unique Identifier : AIDSLINE AIDS/96701878; Vazquez E; Opportunistic infections (OIs) remain a serious problem for HIV-positive patients who remain vulnerable to fungal, parasitic, and bacterial infections. OIs continue to cause severe illness and death in many HIV-positive patients. Researchers are looking at ways to diagnose and prevent PCP, HIV-related cancers,
Women and HIV. Clearinghouse, AIDS Newsletter Database, P.O. Box 6003, Rockville, MD 20849-6003. 800-458-5231 ext. 5714.: Posit Aware. 1996 Sep/Oct;7(5):14-5, 37. Unique Identifier : AIDSLINE AIDS/96701879; Vazquez E; HIV infection rates in women continue to climb and have increased threefold since 1985. HIV infection is now the third leading cause of death in U.S. women aged 25 to 40. Women frequently do not take precautions to protect themselves from sexually transmitted diseases, and are prone to candidiasis. Pregnancy in HIV-po
Treating HIV in 1996. Clearinghouse, AIDS Newsletter Database, P.O. Box 6003, Rockville, MD 20849-6003. 800-458-5231 ext. 5714.: Posit Aware. 1996 Sep/Oct;7(5):17-22. Unique Identifier : AIDSLINE AIDS/96701880; McGuire S; Panel members from the International AIDS Society (IAS) presented the latest trends in AIDS treatment at the Vancouver conference. Guidelines on when to start initial therapy were laid out, and the progression of the primary infection was described. The guidelines recommend treatment with the most potent therapy avail
How low can you go. Clearinghouse, AIDS Newsletter Database, P.O. Box 6003, Rockville, MD 20849-6003. 800-458-5231 ext. 5714.: Posit Aware. 1996 Sep/Oct;7(5):23. Unique Identifier : AIDSLINE AIDS/96701881; Vazquez E; With some treatments reducing viral loads to undetectable levels, there is hope that AIDS may be totally suppressed or eradicated. However, keeping viral loads low requires powerful drug combinations and continuous monitoring. Experts agree that patients must continue drug therapy as a prophylaxis, and that drug-resis
On the other hand...researchers look at who's using which alternative treatments. Clearinghouse, AIDS Newsletter Database, P.O. Box 6003, Rockville, MD 20849-6003. 800-458-5231 ext. 5714.: Posit Aware. 1996 Sep/Oct;7(5):28-9. Unique Identifier : AIDSLINE AIDS/96701882; McGuire S; There is no consensus on the use of alternative therapies in AIDS treatment. However, studies show that anywhere between one-third and all patients use alternative treatments, often in concert with their medically-prescribed regimen. Alternative therapies used include herbal preparations, vitamins and minerals, massag
How much protection is enough? Clearinghouse, AIDS Newsletter Database, P.O. Box 6003, Rockville, MD 20849-6003. 800-458-5231 ext. 5714.: Posit Aware. 1996 Sep/Oct;7(5):31-2. Unique Identifier : AIDSLINE AIDS/96701883; Wakefield SF; Night Ministry, Chicago, IL.; The debate on preventive HIV vaccines at the International AIDS Conference made global economic differences visible. The typical cost of $15,000 per year to treat AIDS patients is beyond the reach of 90 percent of the world s HIV population, most of whom live in Africa and Asia. However, no vaccine developed to date h
Children of the epidemic. Clearinghouse, AIDS Newsletter Database, P.O. Box 6003, Rockville, MD 20849-6003. 800-458-5231 ext. 5714.: Posit Aware. 1996 Sep/Oct;7(5):35-6. Unique Identifier : AIDSLINE AIDS/96701884; Vazquez E; The World Health Organization (WHO) and the United Nations estimate that between 1.3 million and 3 million children worldwide have died of AIDS. Drug therapy may not extend children s lives, but it does provide some benefit in delaying the progression to AIDS. Fewer drugs are approved
Optimism in the North, growing numbers in the South. Clearinghouse, AIDS Newsletter Database, P.O. Box 6003, Rockville, MD 20849-6003. 800-458-5231 ext. 5714.: Posit Aware. 1996 Sep/Oct;7(5):38. Unique Identifier : AIDSLINE AIDS/96701885; McGuire S; People living with HIV in the developed countries of North America, Europe, and Australia have more reason than at any other time in the epidemic s history to be optimistic about being able to live longer and more productively. In those countries, most people either enjoy health
Fauci presents NIAID strategy for HIV vaccine development. National Institute of Allergy and Infectious Diseases. Clearinghouse, AIDS Newsletter Database, P.O. Box 6003, Rockville, MD 20849-6003. 800-458-5231 ext. 5714.: NIAID AIDS Agenda. 1996 Mar;:1, 19. Unique Identifier : AIDSLINE AIDS/96701886; Folkers G; Anthony S. Fauci, M.D., National Institute of Allergy and Infectious Diseases (NIAID) director, presented the strategies for HIV vaccine research and development for the Institute at the Conference on Advances in AIDS Vaccine Development: 1996. The plan, calling for both fundamental and empiric research, seeks also to
CPCRA 007: preliminary results of combination antiretroviral study. Clearinghouse, AIDS Newsletter Database, P.O. Box 6003, Rockville, MD 20849-6003. 800-458-5231 ext. 5714.: NIAID AIDS Agenda. 1996 Mar;:2. Unique Identifier : AIDSLINE AIDS/96701887; Randall P; Preliminary data from the Terry Beirn Community Programs for Clinical Research on AIDS (CPCRA) showed that in patients with no prior use of zidovudine ( AZT ), combination therapy was more effective than
ACTG 152: new insights into pediatric antiretroviral therapy. Clearinghouse, AIDS Newsletter Database, P.O. Box 6003, Rockville, MD 20849-6003. 800-458-5231 ext. 5714.: NIAID AIDS Agenda. 1996 Mar;:3. Unique Identifier : AIDSLINE AIDS/96701888; Bowersox J; Final results of the pediatric clinical trial, AIDS Clinical Trials Group (ACTG) 152, show that initial antiretroviral therapy with didanosine (ddI) alone slows disease progression in HIV-infected children as effectively as combination therapy with ddI and
Two new protease inhibitors approved by FDA. Food and Drug Administration. Clearinghouse, AIDS Newsletter Database, P.O. Box 6003, Rockville, MD 20849-6003. 800-458-5231 ext. 5714.: NIAID AIDS Agenda. 1996 Mar;:4-5. Unique Identifier : AIDSLINE AIDS/96701889; Folkers G; The Food and Drug Administration ( FDA ) approved two new protease inhibitors--ritonavir and indinavir--for the treatment of HIV infection in adults. Ritonavir (
Studies examine relationship of viral load to maternal HIV transmission. Clearinghouse, AIDS Newsletter Database, P.O. Box 6003, Rockville, MD 20849-6003. 800-458-5231 ext. 5714.: NIAID AIDS Agenda. 1996 Mar;:6-7. Unique Identifier : AIDSLINE AIDS/96701890; Doepel LK; The results of several recent studies have shown that HIV transmission from mother to infant is more likely to occur in situations where women have a higher level of HIV RNA in their bloodstream than in women with a smaller viral load. Four separate presentations at the 3rd Conference on Retroviruses and Opportunistic
MACS: maintaining weight decreases risk of death. Clearinghouse, AIDS Newsletter Database, P.O. Box 6003, Rockville, MD 20849-6003. 800-458-5231 ext. 5714.: NIAID AIDS Agenda. 1996 Mar;:8. Unique Identifier : AIDSLINE AIDS/96701891; A recent report from the NIAID-supported Multicenter AIDS Cohort Study (MACS) found that prior to an AIDS diagnosis, men who maintain their weight are more likely to live longer than men who lose too much weight. Previous data predicted early death for persons with AIDS who had severe weight loss. The new findings sug
Two-drug treatment effective against recurrent CMV retinitis. Clearinghouse, AIDS Newsletter Database, P.O. Box 6003, Rockville, MD 20849-6003. 800-458-5231 ext. 5714.: NIAID AIDS Agenda. 1996 Mar;:8. Unique Identifier : AIDSLINE AIDS/96701892; In a study of 279 patients, sponsored by the National Eye Institute, the National Institutes of Allergy and Infectious Diseases (NIAID), and the National Center for Research Resources, investigators found that daily intravenous administration of both foscarnet and ganciclovir is more effective than either drug alone f
3TC treatment may slow HIV mutations, development of drug resistance. Clearinghouse, AIDS Newsletter Database, P.O. Box 6003, Rockville, MD 20849-6003. 800-458-5231 ext. 5714.: NIAID AIDS Agenda. 1996 Mar;:8-9. Unique Identifier : AIDSLINE AIDS/96701893; According to a recent study conducted by the Albert Einstein College of Medicine, HIV develops a mutation (M184V) in patients treated with 3TC (lamivudine). The mutation appears to be resistant to 3TC but decreases the rate at which other mutations de
Miscarriage more likely in HIV-infected women. Clearinghouse, AIDS Newsletter Database, P.O. Box 6003, Rockville, MD 20849-6003. 800-458-5231 ext. 5714.: NIAID AIDS Agenda. 1996 Mar;:9. Unique Identifier : AIDSLINE AIDS/96701894; NIAID-supported researchers at the Baylor College of Medicine found that miscarriage is three times more likely to occur in HIV-infected women than healthy women. More than 11 percent of the 124 HIV-infected women followed had miscarriages. The typical rate is less than 3 percent for non-HIV-infected pregnant women. C
Blacks, Hispanics not at increased risk for AZT side effects. Clearinghouse, AIDS Newsletter Database, P.O. Box 6003, Rockville, MD 20849-6003. 800-458-5231 ext. 5714.: NIAID AIDS Agenda. 1996 Mar;:9, 20. Unique Identifier : AIDSLINE AIDS/96701895; Researchers at the University of California, San Francisco/San Francisco General Hospital analyzed data from two large NIAID-supported studies of AZT monotherapy (ACTG 016 and ACTG 019) and found that black and Hispanic patients with HIV are not at a
Fauci presents new findings on HIV escape mechanisms and HIV suppressor molecules. Clearinghouse, AIDS Newsletter Database, P.O. Box 6003, Rockville, MD 20849-6003. 800-458-5231 ext. 5714.: NIAID AIDS Agenda. 1996 Mar;:10-1. Unique Identifier : AIDSLINE AIDS/96701896; Folkers G; The National Institute of Allergy and Infectious Diseases (NIAID) director, Anthony S. Fauci, M.D., presented findings at the 3rd Conference on Retroviruses and Opportunistic Infections that may help shed light on how HIV escapes the body s immune response following initial infection. NIAID researchers have found that
NIAID international AIDS research. National Institute of Allergy and Infectious Diseases. Clearinghouse, AIDS Newsletter Database, P.O. Box 6003, Rockville, MD 20849-6003. 800-458-5231 ext. 5714.: NIAID AIDS Agenda. 1996 Mar;:12-5. Unique Identifier : AIDSLINE AIDS/96701897; Bowersox J; With the hope of developing a greater understanding of HIV transmission in the developing world, the National Institute of Allergy and Infectious Diseases (NIAID) is supporting its first program of international HIV prevention trials. Investigators will test HIV prevention strategies in Southeast Asia, sub-Saharan Afr
Highlights of AIDS vaccine meeting. Clearinghouse, AIDS Newsletter Database, P.O. Box 6003, Rockville, MD 20849-6003. 800-458-5231 ext. 5714.: NIAID AIDS Agenda. 1996 Mar;:16-9. Unique Identifier : AIDSLINE AIDS/96701898; Doepel LK; Highlights from the Conference on Advances in AIDS Vaccine Development: 1996 at the National Institutes of Health (NIH) on February 11-15, 1996, are described. The need for cooperation from both government and industry in the search for new treatments and a vaccine for HIV was emphasized. Scientists discussed the deve
Putative KS virus grown in laboratory. Clearinghouse, AIDS Newsletter Database, P.O. Box 6003, Rockville, MD 20849-6003. 800-458-5231 ext. 5714.: NIAID AIDS Agenda. 1996 Mar;:20. Unique Identifier : AIDSLINE AIDS/96701899; Folkers G; For the first time in a laboratory, researchers at the University of California, San Francisco, have grown the herpesvirus, thought to cause Kaposi s sarcoma (KS). The virus, known as Kaposi s sarcoma-associated herpes virus (KSHV), was grown in a cell line derived from a lymph system cancer. This advancement may have
NIAID researchers identify cofactors for entry of HIV into cells. National Institute of Allergy and Infectious Diseases. Clearinghouse, AIDS Newsletter Database, P.O. Box 6003, Rockville, MD 20849-6003. 800-458-5231 ext. 5714.: NIAID AIDS Agenda. 1996 Jun;:1, 10-1. Unique Identifier : AIDSLINE AIDS/96701901; Folkers G; Scientists at the National Institute of Allergy and Infectious Diseases (NIAID) report that they have identified fusion cofactors that, for certain strains of HIV-1, make both human and nonhuman CD4+ cells susceptible to HIV fusion and infection. Researchers demonstrated that these HIV-1 strains require, in addition t
Immune system activation boosts HIV replication in HIV-infected people. Clearinghouse, AIDS Newsletter Database, P.O. Box 6003, Rockville, MD 20849-6003. 800-458-5231 ext. 5714.: NIAID AIDS Agenda. 1996 Jun;:3. Unique Identifier : AIDSLINE AIDS/96701902; Folkers G; Researchers at the National Institute of Allergy and Infectious Diseases (NIAID) report that the activation of the immune system by other stimuli results in an increase in HIV replication. Sharilyn Stanley, M.D., NIAID Director Anthony S. Fauci, M.D., and colleagues inoculated 13 asymptomatic HIV-infected people and 1
Low-dose oral alpha interferon study opens. Clearinghouse, AIDS Newsletter Database, P.O. Box 6003, Rockville, MD 20849-6003. 800-458-5231 ext. 5714.: NIAID AIDS Agenda. 1996 Jun;:4-5. Unique Identifier : AIDSLINE AIDS/96701903; Randall P; The National Institute of Allergy and Infectious Diseases (NIAID) is sponsoring a multicenter study to examine the effects of low-dose oral alpha interferon (LDOAI) on the symptoms caused by HIV disease. The four-arm study, to be conducted at 14 sites in the United States , will compare
Gene therapy prolongs CD4+ T cell survival in HIV-infected individuals. Clearinghouse, AIDS Newsletter Database, P.O. Box 6003, Rockville, MD 20849-6003. 800-458-5231 ext. 5714.: NIAID AIDS Agenda. 1996 Jun;:7. Unique Identifier : AIDSLINE AIDS/96701904; Folkers G; Gary Nabel, M.D., Ph.D., of the University of Michigan, and his colleagues report that they can lengthen the survival of important immune system cells, usually depleted during the course of HIV disease, by genetically modifying cells. In the study, supported in part by the National Institute of Allergy and Infectious
Increased risk of cervical abnormalities among HIV-infected African women. Clearinghouse, AIDS Newsletter Database, P.O. Box 6003, Rockville, MD 20849-6003. 800-458-5231 ext. 5714.: NIAID AIDS Agenda. 1996 Jun;:9, 11. Unique Identifier : AIDSLINE AIDS/96701905; Folkers G; A study of 268 women in Malawi (116 HIV-positive women, 152 HIV-negative women) found that the HIV-infected women were 3 times more likely to have persistent human papillomavirus infections (HPV), and twice as likely to have cervical abnormalities. Also, the most immunosuppressed w
Protease inhibitors. Clearinghouse, AIDS Newsletter Database, P.O. Box 6003, Rockville, MD 20849-6003. 800-458-5231 ext. 5714.: Treat Rev. 1996 Aug;(No 22):2-7. Unique Identifier : AIDSLINE AIDS/96701906; There are now nine approved anti-HIV drugs, all of which are meant to keep the level of HIV as low as possible, prevent further damage to the immune system, and stop the progression of the disease. The combination of drugs prescribed depends on which the doctor feels will best stop disease progression based on the sid
A new class of anti-HIV drugs. Clearinghouse, AIDS Newsletter Database, P.O. Box 6003, Rockville, MD 20849-6003. 800-458-5231 ext. 5714.: Treat Rev. 1996 Aug;(No 22):8-9. Unique Identifier : AIDSLINE AIDS/96701907; A new class of anti-HIV drugs has entered the treatment arena. Non-nucleoside reverse transcriptase inhibitors (NNRTIs) interfere with infected cells and suppress their ability to replicate. Delaviradine ( Rescriptor ) and
F-ddA for HIV. Clearinghouse, AIDS Newsletter Database, P.O. Box 6003, Rockville, MD 20849-6003. 800-458-5231 ext. 5714.: Treat Rev. 1996 Aug;(No 22):10. Unique Identifier : AIDSLINE AIDS/96701908; The National Cancer Institute (NCI) is currently testing F-ddA, related to ddI but easier to absorb. To qualify for the trial, patients must have 100-400 T4 counts and have been off all anti-HIV drugs for 3 weeks. Interested patients are directed to call the AIDS Treatment Data Network for a referral.
Garlic for cryptosporidiosis? Clearinghouse, AIDS Newsletter Database, P.O. Box 6003, Rockville, MD 20849-6003. 800-458-5231 ext. 5714.: Treat Rev. 1996 Aug;(No 22):11. Unique Identifier : AIDSLINE AIDS/96701909; The AIDS Research Alliance in California has been testing the effectiveness of garlic in combating cryptosporidiosis, a parasitic infection of the intestinal tract. The test involved patients taking liquid Allicin mixed with distilled water twice daily. Side effects included the expected garlic taste and smell, but pa
Treatments and trials for Kaposi's sarcoma. Clearinghouse, AIDS Newsletter Database, P.O. Box 6003, Rockville, MD 20849-6003. 800-458-5231 ext. 5714.: Treat Rev. 1996 Aug;(No 22):11. Unique Identifier : AIDSLINE AIDS/96701910; A trial at the National Cancer Institute (NCI) is testing the effectiveness of thalidomide in treating Kaposi s sarcoma (KS), a type of cancer that affects many AIDS patients. Thalidomide is thought to inhibit angiogenesis, the development of new blood vessels that contribute to KS progression. Other trials are being
Human growth hormone approved for wasting. Clearinghouse, AIDS Newsletter Database, P.O. Box 6003, Rockville, MD 20849-6003. 800-458-5231 ext. 5714.: AIDS Treat News. 1996 Sep 6;(No 254):1-4. Unique Identifier : AIDSLINE AIDS/96701911; James JS; Serono Laboratories, Inc. has recently been given accelerated Food and Drug Administration ( FDA ) approval for Serostim, a recombinant human growth hormone genetically engineered from mammalian cells, for treatment of AIDS-related wasting. While the price has not been established, Sero
ddI plus d4T. Clearinghouse, AIDS Newsletter Database, P.O. Box 6003, Rockville, MD 20849-6003. 800-458-5231 ext. 5714.: AIDS Treat News. 1996 Sep 6;(No 254):4. Unique Identifier : AIDSLINE AIDS/96701912; James JS; A study of 85 volunteers divided into 5 separate dosage groups found fairly good viral suppression from a combination of didanosine plus stavudine . A 1.3 log viral load reduction was sustained for at least 52 weeks when the 5 dose groups were pooled t
Ritonavir plus saquinavir: two trials with different results. Clearinghouse, AIDS Newsletter Database, P.O. Box 6003, Rockville, MD 20849-6003. 800-458-5231 ext. 5714.: AIDS Treat News. 1996 Sep 6;(No 254):5-6. Unique Identifier : AIDSLINE AIDS/96701913; Mascolini M; Two trials testing the combination of the protease inhibitors , ritonavir and saquinavir, recently came to different conclusions, possibly explained by differences in trial size, drug dosage, and dis
CKR-5--understanding the news. Clearinghouse, AIDS Newsletter Database, P.O. Box 6003, Rockville, MD 20849-6003. 800-458-5231 ext. 5714.: AIDS Treat News. 1996 Sep 6;(No 254):6-7. Unique Identifier : AIDSLINE AIDS/96701914; James JS; A recent discovery about how HIV infects cells and causes disease has revealed that some racial or ethnic groups, but not others, may be very resistant or even immune to HIV infection through sexual transmission. This discovery opens new doors for scientific progress in understanding HIV pathogenesis that may lead to
Power imbalances and therapy.: Focus. 1996 Aug;11(9):1-4. Unique Identifier : AIDSLINE AIDS/96701915; Boyd KK; The therapeutic relationship between a therapist and a client is inherently unbalanced in terms of power. The client invests the therapist with power, which the therapist then uses to help the client empower him/herself. This power imbalance can impede therapy when societal power dynamics, such as race, socioeconomic
Clearinghouse: power and privilege.: Focus. 1996 Aug;11(9):4-5. Unique Identifier : AIDSLINE AIDS/96701916; A bibliography of papers, journal articles, and books related to the power imbalances in the patient-professional relationship is provided. The referenced material considers cultural and ethnic differences, counselor development, empowerment techniques, and countertransference issues in therapy with HIV-positive and A
White privilege and the "silenced dialogue".: Focus. 1996 Aug;11(9):5-6. Unique Identifier : AIDSLINE AIDS/96701917; Kendall FE; The impact of White privilege in the HIV-related counseling and educational environment is explored. The most negative consequence of this phenomenon may be silencing people of other cultures for whom the White frame of reference is not the norm. White counselors often silence others without awareness or intention. Wh
Drug interactions: trials and tribulations.: Crit Path AIDS Proj. 1996 Fall;(No 31):4-6. Unique Identifier : AIDSLINE AIDS/96701918; With the increased availability and use of combination and complementary drug therapies for people living with HIV/AIDS, patients and their physicians now must consider how these new regimens interact. Fifteen drugs are listed with a description of the toxicities or known side effects the drug may cause. Other substan
HIV adult standard of care. ACT UP.: Crit Path AIDS Proj. 1996 Fall;(No 31):10-6. Unique Identifier : AIDSLINE AIDS/96701919; AIDS Coalition To Unleash Power Philadelphia, Philadelphia, PA.; The revised HIV Adult Standard of Care guidelines, produced by ACT UP/Philadelphia, are printed. The extensive table summarizes the minimum standard of care needed for individuals with HIV infection to maximize their quality and length of life. Divided into sections by T4 cell count, the table includes diagnostic test
Eradication of HIV: the cutting edge of clinical trial design.: Crit Path AIDS Proj. 1996 Fall;(No 31):16-7. Unique Identifier : AIDSLINE AIDS/96701920; The AIDS Clinical Trials Group (ACTG) will begin in October 1996, a new clinical trial that will compare three long-term maintenance regimens. Recruits in the randomized double-blind study, ACTG 343, will receive induction therapy with AZT ,
Lethal new worm discovered in PWA.: Crit Path AIDS Proj. 1996 Fall;(No 31):17-8. Unique Identifier : AIDSLINE AIDS/96701921; Doctors recently identified a new form of parasitic worm that was associated with the death of a person with AIDS from the San Francisco Bay area about 1 year ago. The man acquired HIV 5 years ago, but was hospitalized in 1994 with stomach and back pain, weight loss, night sweats and fever. After the worm destroyed pa
Nevirapine, the first of a new class of NNRTI drugs arrives in pharmacies.: Crit Path AIDS Proj. 1996 Fall;(No 31):18-9. Unique Identifier : AIDSLINE AIDS/96701922; Now available in pharmacies, the first of a new class of non-nucleoside reverse transcriptase inhibitors (NNRTIs) has been licensed. Nevirapine (marketed as Viramune ) is different from nucleoside reverse transcriptase inhibitors because it binds at a
Finally--international endorsement of a non-condom HIV prevention alternative.: Crit Path AIDS Proj. 1996 Fall;(No 31):19-20. Unique Identifier : AIDSLINE AIDS/96701923; Forbes A; The Joint United National Programme on HIV/AIDS announced last year that Advantage 24, a Nonoxynol-9 (N-9) product, had been shown to prevent transmission of sexually transmitted diseases, including HIV, during heterosexual vaginal intercourse. Advantage 24 uses a low dose of N-9 with a bio-adhesive gel that forms a t
Medical marijuana--once again--blocked. Marijuana Policy Project.: Crit Path AIDS Proj. 1996 Fall;(No 31):21. Unique Identifier : AIDSLINE AIDS/96701924; Marijuana Policy Project, Washington, DC.; The Clinton Administration is continuing to block the research efforts of Dr. Donald Abrams, University of California, San Francisco, to study the safety and effectiveness of marijuana in stimulating the appetites and reducing nausea of people with AIDS wasting syndrome. Dr. Abrams does not require money for the study
AIDS information on the Internet (Part 2): Critical Path Internet services.: Crit Path AIDS Proj. 1996 Fall;(No 31):27-30. Unique Identifier : AIDSLINE AIDS/96701925; Bauer R; World Wide Web technology on the Internet provides a cost-effective means for reaching AIDS service providers and researchers across the world. It provides a means for obtaining and disseminating information worldwide in a time-sensitive environment. However, because of cost restrictions, many underserved communities
Incoming NTZ blocked by US customs. People With AIDS Health Group.: Crit Path AIDS Proj. 1996 Fall;(No 31):33-4. Unique Identifier : AIDSLINE AIDS/96701926; People With AIDS Health Group, New York, NY.; U.S. Customs in Chula Vista, California, seized an incoming shipment of nitrazoxanide (NTZ), the first drug that shows promise against Cryptosporidium parvum infection in people living with HIV/AIDS. Cryptosporidiosis is a source of diarrhea that has resulted in the death of thousands of people with AIDS. NTZ, approve
AIDS activists secure approval for human growth hormone (Serostim).: Crit Path AIDS Proj. 1996 Fall;(No 31):34. Unique Identifier : AIDSLINE AIDS/96701927; The Food and Drug Administration ( FDA ) has given a verbal commitment to accelerated approval for recombinant human growth hormone (Serostim) for AIDS-associated wasting syndrome. The drug, manufactured by Serono Laboratories, is the first of its kind that directly affects the metaboli
Philadelphia area AIDS/HIV clinical trials.: Crit Path AIDS Proj. 1996 Fall;(No 31):35-9. Unique Identifier : AIDSLINE AIDS/96701928; A listing of currently active clinical trials in the Philadelphia, PA, area is provided. Trials are listed that examine anti-HIV therapies, immune-based therapies, therapies for the prevention of opportunistic infections, and treatments for opportunistic infection and AIDS-related conditions. One study is actively rec
Compassionate use and treatment IND programs.: Crit Path AIDS Proj. 1996 Fall;(No 31):40-67. Unique Identifier : AIDSLINE AIDS/96701929; For individuals with HIV/AIDS who are unable to participate in ongoing clinical trials or who have no other treatment options, compassionate use and treatment IND (Investigational New Drug) programs are available. A fairly inclusive list of drugs for the treatment of HIV disease that are available through compassionat
Benefits planning--what you must know: interview with Daniel Fortuno, AIDS Benefits Counselors. [interview by John S. James]: AIDS Treat News. 1996 Sep 20;(No 255):1, 4-8 cont. Unique Identifier : AIDSLINE AIDS/96701930; Fortuno D; Daniel Fortuno, a counselor with AIDS Benefits Counselors (ABC), summarizes key insurance and benefits information for persons living with AIDS (PWAs), particularly those who reside in California. Fortuno explains the managed care concept and basic health insurance terms, such as pre-existing conditions, health mainte
Nelfinavir (Viracept) expanded access announced.: AIDS Treat News. 1996 Sep 20;(No 255):4. Unique Identifier : AIDSLINE AIDS/96701931; Agouron Pharmaceuticals, Inc. began an expanded-access program for nelfinavir, an experimental protease inhibitor. Qualified patients must be HIV-positive, at least 13 years of age, and have a CD4 count less than or equal to 50. Applicants may not have used nelfinavir previously an
New wave antiretrovirals.: GMHC Treat Issues. 1996 Sep;10(9):1-3. Unique Identifier : AIDSLINE AIDS/96701932; Smart T; Researchers are investigating aspects of the life cycle of HIV that can be exploited by new drugs. Promising compounds include those that block the fusion of HIV to cells; dextran sulfate is an example of such a drug. Reverse transcriptase inhibitors continue to receive attention, with the focus placed on dealing with
Opportunistic infections in Vancouver.: GMHC Treat Issues. 1996 Sep;10(9):4-6. Unique Identifier : AIDSLINE AIDS/96701933; Marco M; Participants at the XI International Conference on AIDS in Vancouver appeared impressed by the improvements being made in the diagnosis, treatment, and prophylaxis of AIDS-related opportunistic infections. Improvements in the following areas are discussed: cytomegalovirus infection
Outdated yet out-of-reach: AIDS society treatment guidelines at the International Conference.: GMHC Treat Issues. 1996 Sep;10(9):7, 10-1. Unique Identifier : AIDSLINE AIDS/96701934; Torres G; The AIDS Society Treatment Guidelines came under scrutiny at the XI International AIDS Conference in Vancouver in 1996. The review panel agreed that treatment needs to be initiated before irreversible immunologic damage occurs. The types of drugs to use for initial therapy (
Police raid buyers' club.: GMHC Treat Issues. 1996 Sep;10(9):8. Unique Identifier : AIDSLINE AIDS/96701935; Police raided the Cannabis Buyers Club and confiscated the club s supply of pure marijuana and drug-laced baked goods. Although the club s purpose was to supply people with AIDS and cancer with marijuana, the California Attorney General s office says healthy people were being supplied as well. Many see the raid as a
CMV retinitis study aborted.: GMHC Treat Issues. 1996 Sep;10(9):8. Unique Identifier : AIDSLINE AIDS/96701936; A study of the experimental anti- cytomegalovirus ( CMV ) drug, MSL-109 manufactured by Protein Design Labs, was halted after an interim analysis found that the treatment offered no benefit over placebo, and that more deaths app
Anabolic steroid boosts weight.: GMHC Treat Issues. 1996 Sep;10(9):8-9. Unique Identifier : AIDSLINE AIDS/96701937; A randomized study of nandrolone decanoate (Deca-Durabolin) showed that the anabolic steroid can increase weight in people with HIV infections. The group receiving nandrolone experienced a greater increase both in fat-free mass and body cell mass (although the latter measure did not reach statistical significance) tha
Delavirdine/protease inhibitor interactions.: GMHC Treat Issues. 1996 Sep;10(9):11-2. Unique Identifier : AIDSLINE AIDS/96701938; Gilden D; On September 27, 1996, the Food and Drug Administration s ( FDA ) Antiviral Drugs Advisory Committee meets to consider licensing the non-nucleoside reverse transcriptase inhibitor (NNRTI), delavirdine (
New York ADAP to cover new AIDS drugs plus viral load testing.: GMHC Treat Issues. 1996 Sep;10(9):12. Unique Identifier : AIDSLINE AIDS/96701939; Link D; New York State, for the first time and after massive grass-roots lobbying, committed millions of State tax dollars to the local AIDS Drug Assistance Program (ADAP). No State has been hit harder by AIDS than New York. As of September 1, 1996, ADAP began covering HIV prot
Antiretrovirals plus immunomodulators: didanosine/interferon-alpha combination shows promise.: NIAID AIDS Agenda. 1996 Jun;:8-9. Unique Identifier : AIDSLINE AIDS/96701943; Folkers G; Researchers at the National Institute of Allergy and Infectious Diseases (NIAID) Clinical Center intramural AIDS program safely administered didanosine (ddI) and interferon-alpha (IFN-alpha) to selected patients for more than 4 years. The study enrolled 36 asymptomatic patients, divided into 12 groups. Each of the gr
Nurses' body fluid exposure reporting, HIV testing, and hepatitis B vaccination rates: before and after implementing universal precautions regulations.: AAOHN J. 1996 Mar;44(3):129-37. Unique Identifier : AIDSLINE MED/96380366; Ramsey PW; Glenn LL; College of Nursing, East Tennessee State University, Johnson; City, USA.; The purpose of this study was to investigate whether mandatory universal precautions changed nurses body fluid exposure and reporting rates, hepatitis B vaccination rates, and human immunodeficiency virus (HIV) testing rates. Random cross-sectional surveys of nurses in Tennessee were conducted in 1991 and 1993 (n = 1
Non-nucleoside anti-HIV-1 reverse transcriptase inhibitors (NNRTIs): a chemical survey from lead compounds to selected drugs for clinical trials.: Farmaco. 1996 May;51(5):305-31. Unique Identifier : AIDSLINE MED/96276270; Artico M; Istituto di Microbiologia, Facolta di Farmacia, Universita di; Roma, La Sapienza, Italy.
Synthesis and antirhinovirus activity of 3-(diethylamino)-5-phenylisoxazole derivatives.: Farmaco. 1996 May;51(5):351-9. Unique Identifier : AIDSLINE MED/96276273; Mazzei M; Garzoglio R; Balbi A; Grandi T; De Montis A; Corrias S; La Colla P; Istituto di Scienze Farmaceutiche, Universita di Genova, Italy.; Previous studies showed that some 2 -alkyloxyisoxazoles 2b-d obtained from 3-(diethylamino)-5-(2 hydroxy-4 -methoxyphenyl)isoxazole 2a were endowed with an interesting anti-group B rhinovirus activity (action on HRV-2 serotype). Other isoxazoles (WIN compounds) are well known to have anti-group A rhinovirus activity (
Synthesis of substituted quinazolone derivatives as potential anti-HIV agents (Part III).: Farmaco. 1996 May;51(5):361-6. Unique Identifier : AIDSLINE MED/96276274; Desai NC; Bhatt JJ; Shah BR; Undavia NK; Trivedi PB; Narayanan V; Department of Chemistry, Bhavnagar University, India.; Several 1-[2-phenyl-4(4H)-oxo-3-quinazolinyl]-2-methyl-4-arylidine 5-oxo-imidazolines (Va-1), 2-phenyl-3-(aroyl amino)-4(4H)-oxo quinazolines (Vla-I) and N1-2-methyl-4(4H)-oxo-3-quinazolinyl-N2-aryl-thioureas (Vlla-k), have been synthesised and tested for anti-HIV activity. The structures of these compounds have been
Synthesis and anti-HIV activity of 10,11-dihydropyrrolo [1,2-b][1,2,5]benzothiadiazepine-11-acetic acid 5,5-dioxide derivatives and related compounds.: Farmaco. 1996 Jun;51(6):425-30. Unique Identifier : AIDSLINE MED/96305743; Silvestri R; Artico M; Pagnozzi E; Stefancich G; Massa S; La Colla P; Loi AG; Spiga MG; Corrias S; Lichino D; Dipartimento di Studi Farmaceutici, Universita di Roma La; Sapienza, Italy.; The synthesis and the in vitro anti-HIV-1 activity of novel pyrrolo annulated benzothiadiazepine acetic acids and some related derivatives are reported. The new compounds share chemical features with pyrrolo[1,2-d][1,4]benzodiazepin-6-one 1 and Ro 5-3335 pyrrylbenzodiazepinone 4, two inhibitors of HIV-replication at t
Evidence that Th1 lymphocytes predominate in islet inflammation and thyroiditis in the BioBreeding (BB) rat.: J Autoimmun. 1996 Jun;9(3):315-9. Unique Identifier : AIDSLINE MED/96413831; Zipris D; Diabetes Division, University of Massachusetts Medical Center,; Worcester 01605, USA.; Th1 cytokines are thought to play a key role in islet inflammation and destruction in insulin-dependent diabetes mellitus (IDDM). We studied this hypothesis in the diabetes-prone (DP)-BB and the diabetes-resistant (DR)-BB rats that are used as a model of human IDDM. The DP-BB rat develops spontaneous autoimmune diabet
Antigen based therapies to prevent diabetes in NOD mice.: J Autoimmun. 1996 Jun;9(3):349-56. Unique Identifier : AIDSLINE MED/96413835; Ramiya VK; Shang XZ; Pharis PG; Wasserfall CH; Stabler TV; Muir AB; Schatz DA; Maclaren NK; Department of Pathology and Laboratory Medicine, University of; Florida, Gainesville 32610-0275, USA.; Interventional approaches that have been successful in delaying insulin-dependent diabetes mellitus (IDDM) using antigen-based immunotherapies include parenteral immunization. It has potential for clinical application provided that effective adjuvants suitable for human use can be found. We have previously shown that
Correlation between viral load measurements and outcome in clinical trials of antiviral drugs.: AIDS. 1995 Dec;9 Suppl 2:S15-S19. Unique Identifier : AIDSLINE MED/96371979; Schooley RT; Infectious Diseases Division, University of Colorado, Denver,; USA.; BACKGROUND: As evidence is emerging that viral load can be correlated with clinical outcome in HIV-infected patients, new assays have been developed to measure viral load in vivo. These include biological assays that involve assessment of viral load by limiting dilution cultures of plasma or peripheral blood mononucle
Clinical experience with saquinavir.: AIDS. 1995 Dec;9 Suppl 2:S21-S25. Unique Identifier : AIDSLINE MED/96371980; Vella S; Laboratory of Virology, Istituto Superiore di Sanita, Rome,; Italy.; BACKGROUND: Saquinavir, a peptide-based, transition-state analogue of a characteristic HIV proteinase cleavage site, is a potent and highly specific inhibitor of HIV-1 and HIV-2 proteinases. COMBINATION THERAPY: Combination therapy with saquinavir at 600 mg and zidovudine at 200 mg, both three times a day, has been sh
Management of cytomegalovirus disease.: AIDS. 1995 Dec;9 Suppl 2:S3-S8. Unique Identifier : AIDSLINE MED/96371977; Danner SA; Academic Medical Centre, Amsterdam, Netherlands.; AIM: To review the estimated incidence of cytomegalovirus ( CMV ) disease, its diagnosis and currently accepted treatments and those under investigation. CMV DISEASE IN PATIENTS WITH HIV INFECTION: The most frequently occurring
Haematopoietic growth factors as supportive therapy in HIV-infected patients.: AIDS. 1995 Dec;9 Suppl 2:S9-S14. Unique Identifier : AIDSLINE MED/96371978; Hermans P; Saint Pierre Hospital, Brussels, Belgium.; BACKGROUND: Neutropenia and anaemia are common problems in patients with HIV infection. Neutropenia can lead to a reduction in drug doses or to withdrawal of important myelosuppressive agents such as ganciclovir, zidovudine, cotrimoxazole and pyrimethamine, while anaemia may require the administration of blood transfu
Drug-resistance patterns of saquinavir and other HIV proteinase inhibitors.: AIDS. 1995 Dec;9 Suppl 2:27-S32. Unique Identifier : AIDSLINE MED/96371981; Roberts NA; Roche Products Ltd, Welwyn Garden City, UK.; AIM: To review available drug-resistance patterns of HIV proteinase inhibitors, in particular saquinavir (formerly known as Ro 31-8959), focusing on the implications for disease management. RESULTS: Reduced sensitivity to saquinavir appears to develop slowly and at low frequency even during prolonged therapy, with an
A benzoic acid glycoside from Geniostoma antherotrichum.: Phytochemistry. 1996 Mar;41(4):1205-7. Unique Identifier : AIDSLINE MED/96351896; Rashid MA; Gustafson KR; Cardellina JH 2nd; Boyd MR; Laboratory of Drug Discovery Research and Development, National; Cancer Institute, Frederick, MD 21702-1201, USA.; Fractionation of an HIV-inhibitory organic extract of Geniostoma antherotrichum afforded a glycoside derivative, which has been characterized as 2-hydroxy-3-O-beta-D-glucopyranosyl-benzoic acid (1) on the basis of spectral analyses. The HIV-inhibitory activity of the extract was traced to polymeric tannins, while 1 wa
Selection and evolution of high-affinity human anti-viral antibodies.: Trends Biotechnol. 1996 Jul;14(7):230-4. Unique Identifier : AIDSLINE MED/96367681; Barbas CF 3rd; Burton DR; Department of Molecular Biology, Scripps Research Institute, La; Jolla, CA 92037, USA.; High-affinity human anti-viral antibodies [e.g. for human immunodeficiency virus type 1 (HIV-1), respiratory syncytial virus (RSV) and herpes simplex virus (HSV)] can be selected from immune phage-display libraries using a variety of strategies. A small subset of these antibodies show potent neutralization in vitro an
[HIV and hepatitis virus infections among prisoners and Police Forces in Rieti District, Italy]: Ann Ig. 1996 Mar-Apr;8(2):291-5. Unique Identifier : AIDSLINE MED/96300712; Bonaventura ME; Marchili M; di Nardo V; Div. Malattie Infettive, Azienda USL Rieti, Ospedale Generale; Provinciale di Rieti.
Extent of undiagnosed HIV infection in hospitalized patients: assessment by linkage of seroprevalence and surveillance methods.: Am J Prev Med. 1996 May-Jun;12(3):195-202. Unique Identifier : AIDSLINE MED/96363820; Trepka MJ; Davidson AJ; Douglas JM Jr; Department of Preventive Medicine University of Colorado Health; Sciences Center, USA.; Routine screening of hospitalized patients for human immunodeficiency virus (HIV) infection has been suggested as a method to identify undiagnosed HIV infection. To evaluate HIV seroprevalence and rates and risk factors for undiagnosed HIV infection among inpatients at an urban hospital, we linked a blinded HIV seropr
HIV sexual risk reduction interventions for women: a review.: Am J Prev Med. 1996 May-Jun;12(3):209-17. Unique Identifier : AIDSLINE MED/96363822; Wingood GM; DiClemente RJ; Department of Health Behavior, School of Public Health,; University of Alabama, Birmingham 35294-2010, USA.; AIDS has emerged as a serious public health threat for women. Reducing the risk for HIV infection among sexually active women requires the adoption of preventive strategies that effectively inhibit viral transmission. However, there is a paucity of published literature describing interventions targeted toward women an
Survival after paraquat poisoning in a HIV positive patient.: Hum Exp Toxicol. 1996 Apr;15(4):286-8. Unique Identifier : AIDSLINE MED/96271964; Ragoucy-Sengler C; Pileire B; Laboratoire de Biochimie-Pharmacologie-Toxicologie, Centre; Hospitalier Regional et Universitaire, Pointe a Pitre,; Guadeloupe FWI.; From 1987 to 1994, 31 cases of acute paraquat poisoning were managed in the CHRU of Pointe a Pitre (FWI). Eighteen patients died, 13 survived. Biological indexes accurately predicted patient s outcome in all cases out of one. In the last case biological parameters were misleading: the corresponding patient survived de
AIDS-related non-Hodgkin's lymphoma presenting as delayed healing of an extraction wound.: Br Dent J. 1996 Aug 10;181(3):102-4. Unique Identifier : AIDSLINE MED/96405985; Nittayananta W; Chungpanich S; Pongpanich S; Mitarnun W; Department of Stomatology, Faculty of Dentistry, Prince of; Songkla University, Thailand.; Non-Hodgkin s lymphoma (NHL) of the oral cavity frequently occurs in patients infected with human immunodeficiency virus (HIV). This report describes a lesion presenting as delayed healing of an extraction wound with hyperaemic swollen gingivae and ulceration in an apparently healthy 34-year-old Thai fisherman. The le
Mucocutaneous manifestations in 22 consecutive cases of primary HIV-1 infection.: Br J Dermatol. 1996 Feb;134(2):257-61. Unique Identifier : AIDSLINE MED/96362624; Lapins J; Lindback S; Lidbrink P; Biberfeld P; Emtestam L; Gaines H; Department of Dermato-Venereology, Huddinge Hospital, Sweden.; Twenty-two consecutive patients presenting with symptomatic human immunodeficiency virus 1 (HIV-1) seroconversion were studied. Most of the patients had a glandular fever-like illness. All patients had fever and pharyngitis, and eight of them also suffered from ulcers of the oral, genital or anal mucosa. Uniform skin
Low incidence of Epstein-Barr virus presence in primary cutaneous T-cell lymphoproliferations.: Br J Dermatol. 1996 Feb;134(2):276-81. Unique Identifier : AIDSLINE MED/96362627; Anagnostopoulos I; Hummel M; Kaudewitz P; Korbjuhn P; Leoncini L; Stein H; Klinikum Benjamin Franklin, Free University Berlin, Germany.; Multiple biopsies taken from 76 European human immunodeficiency virus (HIV)-negative patients with primary cutaneous T-cell lymphoproliferations, including mycosis fungoides (MF), pleomorphic T-cell lymphoma (PMTCL), anaplastic large cell lymphoma (ALCL) and lymphomatoid papulosis (LyP) were investigated for the prese
No detection of HTLV-I proviral DNA in lesional skin biopsies from Swiss and German patients with cutaneous T-cell lymphoma.: Br J Dermatol. 1996 Feb;134(2):282-4. Unique Identifier : AIDSLINE MED/96362628; Boni R; Davis-Daneshfar A; Burg G; Fuchs D; Wood GS; Department of Dermatology, University Hospital of Zurich,; Switzerland.; The search for an infective agent linked to cutaneous T-cell lymphoma (CTCL) has also included the human T-cell lymphotropic virus type I (HTLV-I). Using sensitive techniques such as Southern blotting under low stringency conditions of hybridization and polymerase chain reaction (PCR) with primer sets designed to matc
Fingertip necrosis during chemotherapy with bleomycin, vincristine and methotrexate for HIV-related Kaposi's sarcoma [letter]: Br J Dermatol. 1996 Feb;134(2):378-9. Unique Identifier : AIDSLINE MED/96362655; Pechere M; Zulian GB; Vogel JJ; Jeanpretre M; Hirschel B; Saurat JH
Emergence of CD52-, glycosylphosphatidylinositol-anchor-deficient lymphocytes in rheumatoid arthritis patients following Campath-1H treatment.: Int Immunol. 1996 Mar;8(3):325-34. Unique Identifier : AIDSLINE MED/96362207; Brett SJ; Baxter G; Cooper H; Rowan W; Regan T; Tite J; Rapson N; Molecular Immunology Group, Wellcome Research Laboratories, Kent,; UK.; CD52 is a glycosylphosphatidyl-inositol (GPI)-linked glycoprotein expressed at high levels on normal T and B lymphocytes and at lower levels on monocytes, while being absent on granulocytes and bone marrow stem cell precursors. The emergence of CD52- lymphocytes of both T and B cell lineages was observed in three out
Regulation of house dust mite responses by intranasally administered peptide: transient activation of CD4+ T cells precedes the development of tolerance in vivo.: Int Immunol. 1996 Mar;8(3):335-42. Unique Identifier : AIDSLINE MED/96362208; Hoyne GF; Askonas BA; Hetzel C; Thomas WR; Lamb JR; Department of Biology, Imperial College of Science, Technology; and Medicine, London, UK.; We have previously demonstrated that intranasal (i.n.) administration of an immunodominant peptide (p1-111-139) derived from the house dust mite (HDM) allergen Der p 1 inhibits antigen-specific CD4+ T cell responses in H-2b mice. Here we report that i.n. peptide induced a rapid but transient activation of MHC class II
Effects of different antigenic microenvironments on the course of CD8+ T cell responses in vivo.: Int Immunol. 1996 Mar;8(3):351-8. Unique Identifier : AIDSLINE MED/96362210; Tarazona R; Sponaas Georgia AM; Zhou MM; Schulz R; Tomlinson P; Antoniou J; Mellor AL; Division of Molecular Immunology, National Institute for Medcial; Research, London, UK.; The influence of microenvironment on the course of CD8 + T cell responses in vivo was investigated by injecting H-2Kb-specific T cells from donor TCR transgenic (TCR-Tg) mice into H-2kb-Tg mice. H-2Kb expression in recipients was either ubiquitous (CBK mice) or restricted to myeloid and erythroid cells (K beta mice).
H2-M3wt-restricted, Listeria monocytogenes-specific CD8 T cells recognize a novel, hydrophobic, protease-resistant, periodate-sensitive antigen.: Int Immunol. 1996 Mar;8(3):367-78. Unique Identifier : AIDSLINE MED/96362212; Nataraj C; Brown ML; Poston RM; Shawar SM; Rich RR; Lindahl KF; Kurlander RJ; Department of Medicine, Duke University Medical Center, Durham,; NC 27710, USA.; Mice infected with Listeria monocytogenes (LM) generate H2-M3wt-restricted CD8 effectors which recognize a heat-killed LM-associated antigen (HAA) presented by macrophages. To characterize HAA, we extracted a bioactive component from LM using SDS or NaOH. Extracted HAA aggregated in hydrophilic solvents but dissociate
Evaluation of presence and functional activity of potentially self-reactive T cells in aged mice.: Int Immunol. 1996 Mar;8(3):387-95. Unique Identifier : AIDSLINE MED/96362214; Crisi GM; Tsiagbe VK; Russo C; Basch RS; Thorbecke GJ; Department of Pathology and Kaplan Cancer Center, New York; University School of Medicine, NY 10016, USA.; Autoimmunity is known to increase in aging. A possible factor could be an alteration in the T cell repertoire with advancing age. Antibodies to the variable region of the beta chain of the TCR activate T cells and can serve as probes for analysis of the T cell repertoire. We have used V beta 3 and V beta 17a antibodie
In vitro and in vivo recovery of IFN-gamma, but not IL-2, production by IL-12 in mice with plasma cell tumors.: Int Immunol. 1996 Mar;8(3):413-22. Unique Identifier : AIDSLINE MED/96362217; Ruzek MC; Mathur A; Department of Microbiology, University of Minnesota, Minneapolis; 55455, USA.; We have previously found that T cells from mice bearing plasma cell tumors (PCT mice) demonstrate decreased proliferation as well as decreased production of the Th 1-associated cytokines IL-2 and IFN-gamma in response to polyclonal stimulation. In the present study, weo
Conformational stability of dimeric HIV-1 and HIV-2 reverse transcriptases.: Biochemistry. 1995 Dec 19;34(50):16337-46. Unique Identifier : AIDSLINE MED/96110711; Divita G; Rittinger K; Restle T; Immendorfer U; Goody RS; Max-Planck-Institut fur Medizinische Forschung, Abteilung; Biophysik, Heidelberg, Germany.; The dissociation of dimeric reverse transcriptase (RT) of the human immunodeficiency virus (HIV) types 1 and 2 has been investigated using acetonitrile as a dissociating agent. The equilibrium transitions were monitored by combining different approaches (fluorescence spectroscopy, polymerase activity assay, and size-eo
Biochemical analysis of catalytically crucial aspartate mutants of human immunodeficiency virus type 1 reverse transcriptase.: Biochemistry. 1996 Sep 10;35(36):11536-46. Unique Identifier : AIDSLINE MED/96387193; Kaushik N; Rege N; Yadav PN; Sarafianos SG; Modak MJ; Pandey VN; Department of Biochemistry and Molecular Biology, UMD-New Jersey; Medical School, Newark 07103, USA.; In order to clarify the role(s) of the individual member of the carboxylate triad in the catalytic mechanism of human immunodeficiency virus type 1 (HIV-1) reverse transcriptase, we carried out site-directed mutagenesis of D185, D186, and D110, followed by the extensive characterization of the properties of the indivio
Deoxyadenosine-based DNA polymerase photoprobes: design, synthesis, and characterization as inhibitors of the Escherichia coli DNA polymerase I Klenow fragment.: Biochemistry. 1996 Sep 10;35(36):11634-41. Unique Identifier : AIDSLINE MED/96387203; Moore BM 2nd; Li K; Doughty MB; Department of Medicinal Chemistry, University of Kansas, Lawrence; 66045, USA.; DNA polymerase photoprobes 2-[(4-azidophenacyl)thio]-2 -deoxyadenosine 5 -triphosphate (1), 2-[(4-azidophenylsulfenyl)thio]-2 -deoxyadenosine 5 -triphosphate (2), and 2-[(4-azido-2-nitrophenyl)-thio]-2 -deoxyadenosine 5 -triphosphate (3) were designed from a thermodynamic model of DNA polymerase 1-substrate interactioo
Targeting sites within HIV-1 cDNA with a DNA-cleaving ribozyme.: Biochemistry. 1996 Sep 10;35(36):11693-701. Unique Identifier : AIDSLINE MED/96387210; Raillard SA; Joyce GF; Department of Chemistry, Scripps Research Institute, La Jolla,; California 92037, USA.; A variant of the Tetrahymena ribozyme that efficiently cleaves single-stranded DNA under simulated physiological conditions [Tsang, J., & Joyce, G. F. (1994) Biochemistry 33, 5966-5973] was evaluated as a potential therapeutic agent on the basis of its ability to cleave synthetic oligonucleotide substrates correspo
Incorporation of an artificial protease and nuclease at the HIV-1 Tat binding site of trans-activation responsive RNA.: Bioconjug Chem. 1996 May-Jun;7(3):283-9. Unique Identifier : AIDSLINE MED/96413814; Shah K; Neenhold H; Wang Z; Rana TM; Department of Pharmacology, Robert Wood Johnson Medical; School-UMDNJ, New Jersey 08854, USA.; The synthesis of a C-5 modified uridine phosphoramidite which contains a primary amino group protected with Fmoc is described. During cleavage and deprotection of chemically synthesized RNA, the Fmoc protecting group is removed to yield a free amino group at a predetermined position in the RNA sequence that can be cov
Dystrophin expression in muscles of mdx mice after adenovirus-mediated in vivo gene transfer.: Hum Gene Ther. 1996 Jan 20;7(2):129-40. Unique Identifier : AIDSLINE MED/96380151; Acsadi G; Lochmuller H; Jani A; Huard J; Massie B; Prescott S; Simoneau M; Petrof BJ; Karpati G; Montreal Neurological Institute, McGill University, Canada.; We have generated high-titer adenoviral recombinants (AVR) expressing a 6.3-kb partial dystrophin cDNA insert under the control of either the Rous sarcoma virus (RSV) or cytomegalovirus ( CMV ) promoter. These AVR preparations
Women, contraception and STDs including HIV [editorial]: Int J STD AIDS. 1995 Nov-Dec;6(6):373-86. Unique Identifier : AIDSLINE MED/96256037; Carlin EM; Boag FC; It is estimated that eight million women are infected with the human immunodeficiency virus (HIV) worldwide. Heterosexual transmission is the predominant mode of HIV transmission on a global basis and is becoming increasingly important in the Western world. Women have long used contraceptives as a means of protection
HIV in UK prisons: a review of seroprevalence, transmission and patterns of risk [editorial]: Int J STD AIDS. 1995 Nov-Dec;6(6):387-91. Unique Identifier : AIDSLINE MED/96256038; Curtis SP; Edwards A; Prisons contain individuals at high risk of HIV infection, notably through intravenous drug use. For complex political, social and legal reasons penal institutions in the UK are unable to provide condoms and clean needles. The outbreak of HIV and hepatitis B that occurred in a Scottish prison in 1993 focused attention
Patients misrepresenting their risk factors for AIDS [editorial]: Int J STD AIDS. 1995 Nov-Dec;6(6):392-8. Unique Identifier : AIDSLINE MED/96256039; Brody S; To determine the truthfulness of patients and research subjects self-reports of their sexual and drug use histories in studies of human immunodeficiency virus (HIV) transmission and acquired immunodeficiency syndrome (AIDS) risk factors, studies of or pertinent to lying about AIDS risk factors were extracted from ME
Medical therapy of genital human papilloma virus-related disease.: Int J STD AIDS. 1995 Nov-Dec;6(6):399-407. Unique Identifier : AIDSLINE MED/96256040; Lacey CJ; Fairley I; Department of Genitourinary Medicine, General Infirmary, Leeds,; UK.
Management of mycoses associated with HIV disease.: Int J STD AIDS. 1995 Nov-Dec;6(6):408-12. Unique Identifier : AIDSLINE MED/96256041; Coker RJ; Fisher M; Tomlinson DR; Department of Genitourinary Medicine, St Mary's Hospital, London,; UK.
The case for early intervention ('see and treat') in patients with dyskaryosis on routine cervical screening.: Int J STD AIDS. 1995 Nov-Dec;6(6):415-7. Unique Identifier : AIDSLINE MED/96256042; Murdoch JB; Directorate of Obstetrics, Gynaecology and ENT, St Michael's; Hospital, Bristol, UK.; See and treat colposcopy using an excisional technique (usually LLETZ) is very attractive to patients and practitioners. It is therapeutically effective, efficient and cost-effective within the context of the screening programme. It is, of course, inappropriate to excise the transformation zone of any woman who atte
The case for selective 'see and treat' in patients referred for colposcopy.: Int J STD AIDS. 1995 Nov-Dec;6(6):418-21. Unique Identifier : AIDSLINE MED/96256043; Gardeil F; Turner MJ; Coombe Women's Hospital, Dublin, Ireland.
Chlamydia trachomatis as a possible cofactor for Kaposi's sarcoma in AIDS.: Int J STD AIDS. 1995 Nov-Dec;6(6):422-5. Unique Identifier : AIDSLINE MED/96256044; Peters BS; Thomas BJ; Yi C; Beck EJ; Weber J; Pinching AJ; Taylor-Robinson D; Department of Genitourinary Medicine and Communicable Diseases,; St Mary's Hospital Medical School, London, UK.; AIDS-associated Kaposi s sarcoma (KS) is much more frequent in patients acquiring HIV infection via the sexual route. Epidemiological studies have confirmed the likely involvement of a sexually acquired cofactor in the pathogenesis of this form of KS. We have formulated a set of postulates, epidemiological and experim
Preoperative HIV antibody testing: the views of surgeons and patients.: Int J STD AIDS. 1995 Nov-Dec;6(6):426-30. Unique Identifier : AIDSLINE MED/96256045; Meadows J; Irving G; Chapman K; Gazzard B; Catalan J; Psychological Medicine Unit, Chelsea & Westminster Hospital,; London, UK.; Fifty surgeons and 72 preoperative patients in 2 central London hospitals were asked their views on preoperative HIV antibody testing, who is at risk of HIV infection and HIV test counseling. A substantial proportion of both surgeons and preoperative patients, 48% and 54% respectively, supported compulsory HIV antibod
Multicentre clinical trial with herpes simplex virus vaccine in recurrent herpes infection.: Int J STD AIDS. 1995 Nov-Dec;6(6):431-5. Unique Identifier : AIDSLINE MED/96256046; Mastrolorenzo A; Tiradritti L; Salimbeni L; Zuccati G; Department of Dermatology, STD & AIDS Center, University of; Florence, Italy.; The aim of this work was to confirm our preliminary clinical and immunological evaluation of the protective effects of a herpes simplex virus (HSV) vaccine derived from killed virus in the treatment of relapsing facial or genital herpes simplex infection. A total of 142 patients
Psychosocial differences between recently HIV tested and non-tested gay men who reside in smaller US cities.: Int J STD AIDS. 1995 Nov-Dec;6(6):436-40. Unique Identifier : AIDSLINE MED/96256047; Heckman TG; Kelly JA; Roffman RA; Sikkema KJ; Perry MJ; Solomon LJ; Winett RA; Norman AD; Hoffmann RG; Stevenson LY; Center for AIDS Intervention Research, Medical College of; Wisconsin, Milwaukee 53226, USA.; While a number of studies have examined behavioural and psychosocial correlates of HIV test seeking, most of this research has relied on samples of urban gay men. Less is known about HIV testing rates and factors associated with testing among gay and bisexual men who live in smaller cities. The present research admini
Prevalence of blood-borne viruses among intravenous drug users and alcoholics in Hiroshima, Japan.: Int J STD AIDS. 1995 Nov-Dec;6(6):441-3. Unique Identifier : AIDSLINE MED/96256048; Ichimura H; Kurimura O; Tamura I; Tsukue I; Tsuchie H; Kurimura T; Institute of Clinical Research, Kure National Hospital,; Hiroshima, Japan.; We investigated the prevalence of human immunodeficiency viruses-1 and 2 (HIV-1 and HIV-2), human T-lymphotropic virus type I and II, hepatitis B virus (HBV), hepatitis C virus (HCV) and hepatitis D virus among intravenous drug users (IVDU) in Hiroshima, Japan , where little is known
Lifetime cost of treating a person with HIV infection.: Int J STD AIDS. 1995 Nov-Dec;6(6):444-6. Unique Identifier : AIDSLINE MED/96256049; Jebakumar SP; Woolley PD; Curless E; Department of GU Medicine, University Hospital of South; Manchester, UK.; A study was conducted to examine the inpatient, outpatient and drug therapy costs incurred from initial presentation with HIV infection or AIDS to death, where death occurred between 1990 and 1994. The average lifetime cost per patient was 18,729 pounds being made up of 8428 pounds for inpatient care, 2086 pounds for
Spectrum of opportunistic infections among AIDS patients in Tamil Nadu, India.: Int J STD AIDS. 1995 Nov-Dec;6(6):447-9. Unique Identifier : AIDSLINE MED/96256050; Kumarasamy N; Solomon S; Jayaker Paul SA; Venilla R; Amalraj RE; Government General Hospital, Madras, India.; A retrospective case note review of 100 AIDS patients attending a large Indian centre was performed. Of these 100 patients, 94% gave a history of heterosexual HIV transmission, 68% were male. The majority of females were aged 21 to 30 years. The most common mode of presentation was tuberculosis (61%), both pulmonary (
Erythema multiforme secondary to dideoxycytidine (ddC).: Int J STD AIDS. 1995 Nov-Dec;6(6):450. Unique Identifier : AIDSLINE MED/96256051; Wardropper AG; Ong EL; Department of Genitourinary Medicine, Newcastle General Hospital,; Newcastle upon Tyne, UK.
Phthirus pubis infestation of the eyelids: a marker for sexually transmitted diseases.: Int J STD AIDS. 1995 Nov-Dec;6(6):451-2. Unique Identifier : AIDSLINE MED/96256052; Skinner CJ; Viswalingam ND; Goh BT; Royal Hospitals Trust, London, UK.
The value of an additional diagnostic test for first attacks of genital herpes.: Int J STD AIDS. 1995 Nov-Dec;6(6):453. Unique Identifier : AIDSLINE MED/96256053; Watson PG; Pattman RS; Sankar KN; Wardropper AG; Department of Genitourinary Medicine, Newcastle General Hospital,; Newcastle upon Tyne, UK.
Successful prevention of recurrent pneumonia caused by Pseudomonas aeruginosa in a patient with AIDS [letter]: Int J STD AIDS. 1995 Nov-Dec;6(6):454-5. Unique Identifier : AIDSLINE MED/96256054; Ainsworth J
The use of central venous catheters in patients with HIV [letter]: Int J STD AIDS. 1995 Nov-Dec;6(6):455-6. Unique Identifier : AIDSLINE MED/96256055; Dimian CO; Bingham JS
HIV prevalence among blood donors correlates with hospital STD rate in Maharashtra, India [letter]: Int J STD AIDS. 1995 Nov-Dec;6(6):456. Unique Identifier : AIDSLINE MED/96256056; Salunke SR; Jagtap MR; Hira SK
Chlamydia trachomatis prevalence in high risk women, Tijuana, Mexico, 1993--a pilot study [letter]: Int J STD AIDS. 1995 Nov-Dec;6(6):456-8. Unique Identifier : AIDSLINE MED/96256057; Gunn RA; Valdez Oropeza E; Santaella A; Peter CR
Fellatio in the sexual transmission of Lancefield Group A beta-haemolytic streptococcus [letter]: Int J STD AIDS. 1995 Nov-Dec;6(6):458. Unique Identifier : AIDSLINE MED/96256058; Fisk P; Riley V
Quantification of zidovudine and individual zidovudine phosphates in peripheral blood mononuclear cells by a combined isocratic high performance liquid chromatography radioimmunoassay method.: J Pharm Biomed Anal. 1996 Feb;14(4):491-9. Unique Identifier : AIDSLINE MED/96362400; Peter K; Lalezari JP; Gambertoglio JG; Division of Clinical Pharmacy, University of California, San; Francisco 94143-0622, USA.; Zidovudine (ZDV, AZT ) is the first clinically effective drug licensed for use in the treatment of human immunodeficiency virus (HIV) infection. Activation of ZDV requires phosphorylation to ZDV triphosphate by cellular kinases. It is important, theref
Aborigines and tuberculosis: why they are at risk.: Aust J Public Health. 1995 Oct;19(5):487-91. Unique Identifier : AIDSLINE MED/96342472; Plant AJ; Krause VL; Condon JR; Kerr C; National Centre for Epidemiology and Population Health,; Australian National University, Canberra.; Aborigines have higher rates of Mycobacterium tuberculosis than the rest of the community. There are insufficient contemporary data to assess how much risk tuberculosis poses to the Aboriginal community. Tuberculosis is of particular concern because of its interaction with human immuno-deficiency virus (HIV). We aimed
Infection control and human immunodeficiency virus: perceptions of risk among nurses and hospital domestic workers.: Aust J Public Health. 1995 Oct;19(5):492-500. Unique Identifier : AIDSLINE MED/96342473; Parsons CD; Spicer MJ; Richardson M; Peterson C; Watson LF; Centre for Research in Public Health and Nursing, La Trobe; University, Melbourne.; In December 1993 the first case of patient-to-patient transmission of human immunodeficiency virus (HIV), at a doctor s surgery in New South Wales, was documented. In an environment of heightened anxiety about HIV transmission and the adequacy of infection-control measures taken by health providers, it is important to
[Expression of HIV-1 epitopes included in particles formed by human hepatitis B virus nucleocapsid protein]: Biokhimiia. 1996 Mar;61(3):532-45. Unique Identifier : AIDSLINE MED/96319939; Isaguliants MG; Kadoshnikov IuP; Kalinina TI; Khuliakov IuE; Semiletov IuA; Smirnov VD; Wahren B; Swedish Institute for Infectious Disease Control, Stockholm,; Sweden.; Hybrids of the core protein of hepatitis B virus (HBcAg) have been designed which carry N-terminal insertions of B- and T-cell epitopes of HIV-1 an immunodominant B-epitope from gp41, a T-cell epitope from p34 pol, and a cluster of B- and T-cell epitopes from p17 gag. The hybrids have been synthesized using two expres
Clinical significance of drug resistance in human immunodeficiency virus.: Clin Infect Dis. 1995 Oct;21 Suppl 2:S166-9. Unique Identifier : AIDSLINE MED/96114198; Richman DD; Department of Pathology, Department of Veterans Affairs Medical; Center, San Diego, California, USA.; Antiretroviral drugs exert only limited activity against viruses that replicate persistently to high levels. Thus, drug-resistant viruses readily emerge. It has been difficult to assess the contribution of such drug resistance to the failure of treatment with drugs that have only limited effectiveness in the first pla
Molecular detection of human cytomegalovirus and determination of genotypic ganciclovir resistance in clinical specimens.: Clin Infect Dis. 1995 Oct;21 Suppl 2:S170-3. Unique Identifier : AIDSLINE MED/96114199; Spector SA; Hsia K; Wolf D; Shinkai M; Smith I; Department of Pediatrics, University of California, San Diego, La; Jolla 92093-0672, USA.; The data presented in this article demonstrate how the polymerase chain reaction (PCR) can be used to detect human cytomegalovirus (HCMV) DNA in the plasma and cerebrospinal fluid (CSF) of infected individuals. Detection of HCMV DNA in plasma of transplant recipients and persons in
Clinical impact of cytomegalovirus infections of the nervous system in patients with AIDS.: Clin Infect Dis. 1995 Oct;21 Suppl 2:S196-201. Unique Identifier : AIDSLINE MED/96114205; McCutchan JA; Department of Medicine, University of California, San Diego, USA.; Cytomegalovirus ( CMV ) causes five distinct neurological syndromes in patients with AIDS: retinitis, myelitis/polyradiculopathy, encephalitis with dementia , ventriculoencephalitis, and mononeuritis multiplex. The clinical synd
Cytomegalovirus-induced alveolar hemorrhage in patients with AIDS: a new clinical entity?: Clin Infect Dis. 1996 Apr;22(4):616-20. Unique Identifier : AIDSLINE MED/96362427; Herry I; Cadranel J; Antoine M; Meharzi J; Michelson S; Parrot A; Rozenbaum W; Mayaud C; Service de Pneumologie, Hopital Tenon, Paris, France.; We report five cases of alveolar hemorrhage associated with intravascular hemolysis in patients with AIDS. Cytomegalovirus was the only pathogen recovered from the lungs of these patients. There was evidence of multivisceral spread of the virus in all patients, and all had viremia. All had clinical, biological, and pa
AIDS-associated cytomegalovirus infection mimicking central nervous system tumors: a diagnostic challenge.: Clin Infect Dis. 1996 Apr;22(4):626-31. Unique Identifier : AIDSLINE MED/96362429; Moulignier A; Mikol J; Gonzalez-Canali G; Polivka M; Pialoux G; Welker Y; Alain S; Thiebaut JB; Dupont B; Services des Maladies Infectieuses et tropicales, Hopital de; l'Institut Pasteur, Paris.; We reviewed cases of cytomegalovirus ( CMV ) infection of the central nervous system (CNS) that initially masqueraded as tumors in 37 of 543 consecutive patients infected with human immunodeficiency virus (HIV) and CMV who were
Infectious etiologies of rhabdomyolysis: three case reports and review.: Clin Infect Dis. 1996 Apr;22(4):642-9. Unique Identifier : AIDSLINE MED/96362432; Singh U; Scheld WM; Department of Internal Medicine, University of Virginia Health; Sciences Center, Charlottesville 22908, USA.; Rhabdomyolysis can be precipitated by trauma, ischemia, metabolic defects, electrolyte abnormalities, drugs, and a wide variety of infectious diseases. At our institution, recent cases of rhabdomyolysis induced by influenza prompted us to review the infectious etiologies of this entity. In addition, a thorough literat
Increased levels of nitrite in the sera of children infected with human immunodeficiency virus type 1.: Clin Infect Dis. 1996 Apr;22(4):650-3. Unique Identifier : AIDSLINE MED/96362433; Torre D; Ferrario G; Speranza F; Martegani R; Zeroli C; Division of Infectious Diseases, Regional Hospital, Varese,; Italy.; Nitric oxide (NO) is a newly discovered gas that plays an important role in cell communication and host resistance to infection. The production of NO was examined in the sera of seven children infected with human immunodeficiency virus type 1 (HIV-1) and in the sera of 14 children who became seronegative for HIV-1 dur
Cavitary pulmonary lesions in patients infected with human immunodeficiency virus.: Clin Infect Dis. 1996 Apr;22(4):671-82. Unique Identifier : AIDSLINE MED/96362436; Gallant JE; Ko AH; Department of Medicine, Johns Hopkins University School of; Medicine, Baltimore, Maryland 21287-6220, USA.; The differential diagnosis of cavitary pulmonary lesions in individuals infected with human immunodeficiency virus (HIV) is broad, especially in patients with advanced disease. In patients with Pneumocystis carinii pneumonia, cavitation is an uncommon manifestation of a common disease. It is unusual in patients with p
Tuberculosis in patients infected with human immunodeficiency virus: perspective on the past